Last Updated: August 25, 2026 TL;DR: Palestine is a market defined by two things a supplier has to plan around: a two-sided clearance requirement, and a public procurement channel that only a local partner can enter. Medicines are regulated by the General Directorate of Pharmacy and its Drug Registration Department within the Palestinian Ministry of Health, and the US International Trade Administration records that both Israeli and Palestinian Ministry of Health approvals and registrations are required before pharmaceuticals are shipped into the West Bank and Gaza. The Ministry of Health tenders twice a year and only prequalified Palestinian importers and distributors may bid, so a foreign manufacturer competes through a local partner rather than directly. The high-complexity categories – oncology, HIV, tuberculosis, epilepsy and psychiatry – have long been procured abroad. Farbe Firma Pvt Ltd fills sterile injectables on ISO Class 5 aseptic lines in a WHO-GMP certified facility in Gujarat, India, and builds the dossier, batch and bilingual artwork documentation a Palestinian importer needs to carry a product through both clearances and into a tender. Key Takeaways Plan for two regulatory clearances, not one. The US International Trade Administration's commercial guide for the West Bank and Gaza states plainly that Israeli and Palestinian Ministry of Health approvals and registrations are both required before any pharmaceutical, medical device or piece of medical equipment is shipped in. Treat this as an operational fact to be scheduled and documented rather than a formality: it changes lead times, it changes which certificates an importer will ask you for, and it is the single most common reason a first-time exporter's timeline slips. The Palestinian side of that process sits with the Drug Registration Department of the General Directorate of Pharmacy. Public tenders run through prequalified Palestinian companies, twice a year. The Ministry of Health issues tenders for pharmaceuticals, medical equipment and supplies on a twice-yearly cycle, and only prequalified Palestinian importers and distributors are permitted to bid. A manufacturer outside Palestine therefore does not win a Ministry tender – its local partner does, using the manufacturer's documentation. That makes the quality of what you hand your distributor – certificates of analysis, stability summaries, GMP evidence, bilingual artwork, plant and process documentation – the actual competitive variable. The specialist and injectable-heavy categories are structurally imported. Palestine has six pharmaceutical factories in the West Bank and local manufacturing is the territory's only domestic medical-products industry, but the published account of the sector records that around 40% of Ministry of Health medicines are procured from Palestinian companies and that complex products for HIV, tuberculosis, oncology, epilepsy and psychiatry are always procured abroad. Those are precisely the therapeutic areas where sterile injectables and cytotoxic handling matter most, and they are where an external manufacturer is filling a structural gap rather than displacing local industry. Supply continuity is being measured, published and treated as the headline problem. WHO's occupied Palestinian territory situation update covering the period to 31 January 2026 reported 51% of essential medicines at zero stock across the Gaza Strip, including 66% in chemotherapy and blood diseases and 46% in kidney transplantation and haemodialysis. In the West Bank, the Palestinian Ministry of Health stated on 4 June 2026 that 180 of the 520 essential medicines it supplies and 50 of 97 oncology medicines were at zero stock. For a procurement buyer, the practical lesson is that a supplier is judged on whether it can hold a delivery schedule and re-supply against a moving import window. Introduction: Why Palestine Demands a Premium Injectable Manufacturer in Palestine Palestine is a small market with unusually demanding logistics, and the suppliers who do well there are the ones who understand that before they quote. Medicines regulation sits with the General Directorate of Pharmacy inside the Palestinian Ministry of Health in Ramallah – a directorate, not a standalone agency – and its Drug Registration Department handles marketing authorisation alongside inspection, import control, licensing, market control, quality control, advertising control, clinical trial control and pharmacovigilance. Importers, wholesalers and distributors are licensed by the Ministry, and manufacturers supplying the market are expected to comply with GMP. The Palestinian Essential Medicine List published for 2024 runs to 653 items across 463 active ingredients, and the Ministry stated in June 2026 that it supplies 520 essential medicines and 97 cancer medicines – the procured subset of that list, and a useful map of where a supplier's portfolio might fit. What makes the market genuinely different from its neighbours is the import architecture. Under the 1994 Protocol on Economic Relations, Israel and the Palestinian Authority operate within a single customs and tax envelope, with Israel collecting customs and VAT on the Authority's behalf. In practice, as the US International Trade Administration records, that means pharmaceuticals bound for the West Bank and Gaza need approvals and registrations on both the Israeli and the Palestinian side before shipping. None of this is something a foreign manufacturer can shortcut, and none of it is something a Palestinian importer can absorb alone. Choosing an injectable manufacturer in Palestine's supply chain therefore means choosing one whose documentation is complete, current and reissued on request without argument, because that documentation will be presented more than once, to more than one authority, on a timetable nobody fully controls. What Sets a World-Class Injectable Manufacturer in Palestine Apart The first differentiator is honesty about what is and is not published. Palestine does not publish a dossier format, a review timeline, a fee schedule or a registration validity period that we can point to, and any supplier who quotes you a confident number for a Palestinian registration timeline is inventing it. What is documented is the shape of the system: products must be registered before marketing; the review considers constituents, manufacturing procedure, quality control procedures, stability studies and clinical information; the Drug Registration Department issues registration certificates as well as Certificates of Pharmaceutical Product and Free Sale Certificates; and medication inserts must be bilingual in Arabic and English. A serious partner tells you that boundary and then prepares a file that would satisfy a strict reviewer in any comparable Eastern Mediterranean market, rather than guessing at a checklist. The second is fitness for the channel you are actually selling into. Alongside Ministry tenders, a significant volume of medicines reaches Palestinian patients through humanitarian and UN procurement. WHO is the dominant mover of medical supplies into Gaza, reporting more than 923 medical supply trucks since October 2023 including 640 of its own, and UNRWA runs a supplier prequalification process under which only prequalified suppliers may take part in subsequent procurement. UN agency procurement generally runs through WHO Prequalification and assessment against WHO GMP, so a manufacturer whose quality system is already built to that reference has a credible path into the channel. The same manufacturer must also be able to supply in the pack sizes and batch quantities these buyers order, which are rarely the quantities a national tender uses. Quality Systems Behind Every Sterile Injectable Farbe Firma fills sterile injectables on ISO Class 5 aseptic lines inside a WHO-GMP certified facility in Gujarat, India. Sterility assurance is designed into the process rather than inferred from a final test: terminal sterilisation or aseptic processing is selected on the product's own merits, supported by media fill validation, routine environmental and personnel monitoring, container closure integrity testing and a documented contamination control strategy. Release testing runs on HPLC and GC for assay and related substances, LAL for bacterial endotoxins, Karl Fischer for water content where the presentation calls for it, and full compendial sterility testing. Every batch ships with a certificate of analysis that a reviewer on either side of the import route can read without a covering explanation. Stability is generated to ICH Q1A(R2) with photostability under ICH Q1B, in the container-closure system that will actually ship, and defended on hot-climate conditions rather than temperate ones – the right posture for a route that may involve extended port and inland holding times in an Eastern Mediterranean summer. Dossiers are compiled in CTD structure, which is the most portable starting point when a target market has not published a format of its own, and the compendial reference set covers IP, USP, BP and EP. Package inserts and outer artwork are produced bilingually in Arabic and English as the Palestinian Ministry of Health requires, with artwork files supplied in editable form so a local importer can respond to an artwork query without waiting on a new production cycle. Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry Why Farbe Firma is the Trusted Injectable Manufacturer in Palestine for Global Buyers The most useful thing a manufacturer can offer a Palestinian buyer right now is predictability, and it is worth being precise about why. The Palestinian Ministry of Health's own June 2026 statement described 180 of 520 essential medicines and 50 of 97 oncology medicines at zero stock in the West Bank, along with 265 specialised medical consumables and 79 laboratory items, and singled out dialysis filters, surgical sutures and cardiac catheterisation supplies. It reported roughly 19,500 surgeries performed in government hospitals between 1 January and 1 June 2026 and more than 11,000 scheduled surgeries postponed. WHO's January 2026 update recorded 18 of Gaza's 36 hospitals partially functional with none fully functional, 3,057 hospital beds including 116 ICU beds, and 641 patients on haemodialysis across four hospitals against a Ministry estimate of up to 1,100 needing it. We cite these figures for one reason: they describe the operating conditions a supplier is being asked to perform in, and they explain why buyers weight schedule reliability and documentation over unit price. India is already an established origin for medicines reaching Palestine, through both commercial and government channels. UN COMTRADE data reported via Trading Economics puts Palestinian imports of HS Chapter 30 pharmaceutical products from India at about US$7.25 million in 2023, of which roughly US$5.00 million was medicaments in retail packings and US$1.90 million blood fractions, antisera, vaccines and toxins. Separately, the Government of India dispatched humanitarian consignments to Palestine through UNRWA in October 2024 – an initial tranche of around 30 tonnes of medicines and food items on 22 October, followed on 29 October by a further 30 tonnes of medical supplies described as including essential life-saving and anti-cancer drugs. For a Palestinian importer, that means Indian-origin product is neither novel nor unfamiliar to the people who will handle the file. Farbe Firma Pvt Ltd works as both manufacturer and CDMO, which suits a market where a single product may need to serve a Ministry tender, a private importer and a humanitarian order on three different clocks. We support bilingual Arabic and English artwork and package inserts, flexible batch sizes so a distributor is not forced to buy tender-scale quantities for a private channel, CTD-structured dossier compilation, and the GMP certificates, plant and company profiles, process validation protocols, stability summaries and per-batch certificates of analysis that a prequalified Palestinian importer needs in order to complete a tender submission and clear both sides of the import route. Contract development and manufacturing, own-label supply and technology transfer all run on the same quality system. Because requirements here can change faster than they are published, we also expect buyers to reconfirm current documentation requirements with the General Directorate of Pharmacy before a shipment is committed, and we reissue paperwork to match. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Who regulates medicines and injectables in Palestine? Regulation sits with the General Directorate of Pharmacy within the Palestinian Ministry of Health in Ramallah, and specifically with its Drug Registration Department. It is a directorate of the Ministry rather than a standalone medicines agency, and its published remit covers marketing authorisation, inspection, import control, licensing of importers, wholesalers and distributors, market control, quality control, control of medicine advertising and promotion, clinical trial control and pharmacovigilance. The same department issues Certificates of Pharmaceutical Product and Free Sale Certificates. Because published procedural detail is limited, importers should confirm current requirements with the Directorate directly rather than relying on secondary summaries. Does a product need Israeli approval as well as Palestinian approval? In practice, yes. The US International Trade Administration's commercial guide for the West Bank and Gaza states that Israeli and Palestinian Ministry of Health approvals and registrations are required prior to shipping any pharmaceutical, medical equipment or device into the West Bank and Gaza. This follows from the 1994 Protocol on Economic Relations, under which Israel and the Palestinian Authority operate within a single customs and tax envelope. We state this as an operational fact that affects scheduling and documentation, and we recommend that importers verify the current mechanics on both sides before committing a shipment, since we have not found a published, current description of the Israeli-side process. How does a foreign manufacturer sell into Palestinian Ministry of Health tenders? Through a prequalified local partner. The Ministry of Health issues tenders for pharmaceuticals, medical equipment and supplies twice a year, and only prequalified Palestinian importers and distributors are allowed to bid. A manufacturer outside Palestine supports that partner rather than bidding itself, which means the manufacturer's contribution is documentary: GMP evidence, stability data, certificates of analysis, bilingual artwork, plant and process documentation, and a reliable commitment on lead times and pack sizes. Public-sector stock is then distributed through the Ministry's central warehouses to public hospitals and clinics. What language must labelling and package inserts be in? Palestinian Ministry of Health requirements are for medication inserts to be bilingual in Arabic and English. Published guidance on design and length is limited, so the practical approach is to prepare artwork that is bilingual, legible at the pack sizes actually used, and supplied in editable source files so that an importer can respond quickly if a reviewer asks for a change. Farbe Firma prepares Arabic and English artwork and inserts as standard for this market. What makes Farbe Firma a suitable injectable manufacturer for Palestine? Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling on ISO Class 5 aseptic lines and exporting to more than 30 countries. For Palestine specifically we compile CTD-structured dossiers, generate ICH Q1A(R2) and Q1B stability data defended on hot-climate conditions, produce bilingual Arabic and English artwork and inserts, and supply the GMP certificates, process validation protocols, stability summaries and per-batch certificates of analysis a prequalified Palestinian importer needs for a tender file and for clearance. We also work in the smaller batch sizes that private and humanitarian orders use. Contact info@farbefirma.com to discuss a specific molecule, tender or own-label programme. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: August 28, 2026 TL;DR: Eritrea is one of the least documented medicines markets in the world, and the honest starting point is to say so. There is essentially one paragraph of public description of how medicines are registered there – an undated summary on the African Medicines Regulatory Harmonisation country page – and it tells you two useful things: a first submission to the National Medicines and Food Administration is treated as a new application, and a manufacturer whose site the regulator has not previously inspected and approved must submit a Site Master File, with a GMP inspection possible. Dossier format, certificate requirements, fees, validity and timelines are not published anywhere we could reach. Structurally the market is simple: PHARMECOR, the state pharmaceutical and medical supplies corporation, imports and distributes – 85% to Ministry of Health facilities and 15% to other public institutions and private pharmacies in the first half of 2025 – and the Ministry of Health is the sole Global Fund Principal Recipient on every grant since 2003. The binding constraint is not regulatory. It is payment: the Nakfa is not convertible and the National Bank of Eritrea must approve every cross-border transfer. Key Takeaways The registration requirements are not published, and your first deliverable is a letter, not a dossier. The only public description of the National Medicines and Food Administration's process states that a first application is treated as a new application, that medicines from facilities the regulator has not previously inspected and approved require a Site Master File, and that the regulator may also conduct a GMP inspection. Beyond that – whether CTD or ACTD is expected, whether a WHO certificate of a pharmaceutical product or a GMP certificate is required, what samples or fees are needed, how long a review takes and how long an approval lasts – nothing is published. Even the regulator's name appears in three different forms in Eritrean government output. Any supplier who quotes you a confident Eritrean dossier checklist is quoting something they cannot source. There is one documented counterparty. PHARMECOR, the Pharmaceutical and Medical Supplies Corporation of Eritrea, imports and distributes medicines, and the Ministry of Information reports that it distributed 351 million Nakfa of medicines and equipment in the first half of 2025, 85% to Ministry of Health facilities and 15% to other government institutions and private pharmacies, having distributed 606 million Nakfa in 2023 on a 79/21 split. It states that it imported over US$32 million of supplies in 2023 and over US$8 million in the first half of 2025, and that technical, quality and financial inspections are carried out with the national regulator both before procurement and before items enter service. Whether any private import channel exists in law is not documented either way. Payment is the real risk, and it should be priced before the product is. The United States Department of State's investment climate reporting records that the Nakfa is not convertible, that the exchange rate is set by government and does not fluctuate, that the National Bank of Eritrea must approve and manage all fund transfers into and out of the country and can decline them, that foreign banks may not operate in Eritrea, and that organisations have found it difficult to move foreign currency even to pay essential bills abroad. It also records that public procurement policies are not publicised and the national budget is not public. For an exporter this converts a market-entry question into a counterparty and settlement question. The donor channel is where the volume and the timing are. The Global Fund has financed ten grants in Eritrea since 2003 and the Ministry of Health is the Principal Recipient on all of them; the three active grants covering HIV, tuberculosis and malaria carry signed amounts of roughly US$117.3 million, US$28.8 million and US$87.6 million respectively and are currently scheduled to run to 31 December 2026, with the next-cycle funding requests submitted in May 2023. On the product side WHO's 2024 Eritrea malaria profile records injectable artesunate as the national treatment for severe malaria, adopted in 2015, with 71% of the population living in high-transmission areas and around 220,000 estimated cases a year. A supplier who wants to be relevant to the next cycle needs to be visible now. Introduction: Why Eritrea Demands a Premium Injectable Manufacturer in Eritrea Eritrea is a market of roughly 3.6 million people – the World Bank puts the 2025 population at 3,607,003 – with a health system operating on very little money. Current health expenditure was US$28.30 per person in 2023 on the World Bank's estimate, and the Bank's last observation for gross national income per capita is US$650, recorded for 2011; there is no observation for any year since. That absence is itself a fact worth stating, because it tells you how much of what you will read about Eritrea is estimate rather than measurement. What the health data does show is a system delivering more than its budget suggests: immunisation coverage with three doses of DPT has held at 95% across 2022, 2023 and 2024, life expectancy was 68.9 years in 2024, and maternal mortality fell from 363 per 100,000 live births in 2018 to 291 in 2023. Tuberculosis incidence was 115 per 100,000 in 2024 and HIV prevalence among adults 0.4%. The injectable demand profile follows directly from that. WHO's Eritrea malaria profile of December 2024, with data validated by the country in November 2024, records injectable artesunate as national policy for severe malaria since 2015, 71% of the population living in high-transmission areas, an estimated 220,000 cases and 459 deaths in 2023, and pyrethroid resistance confirmed at every site tested. Add maternal health, anaesthesia, anti-infectives and a routine immunisation programme running at 95% coverage, and the shape of the requirement is clear enough. What is not clear – and this is the honest difficulty of writing about Eritrea – is the procedure by which a foreign manufacturer becomes an approved supplier of those products. The rest of this article separates what is documented from what is not, because for this market that distinction is more valuable than any amount of confident-sounding guidance. What Sets a World-Class Injectable Manufacturer in Eritrea Apart Start with what is actually established. Eritrea's medicines regulator sits within the Ministry of Health and is most commonly referred to as the National Medicines and Food Administration, although Eritrean government publications have also called it the National Food and Medicine Safety Control and the National Food and Medicines Control; we have not found an instrument settling which is the current statutory name, and we are not going to pretend otherwise. The African Medicines Regulatory Harmonisation country profile states plainly that there has been no national health act or overarching regulation in Eritrea, but that there are several proclamations covering the control of drugs, cosmetics and sanitary items among other subjects. Those proclamations are referred to without number, date or link, and no Eritrean government gazette is available online. So the legal basis of medicines control exists and is referenced by a continental body, but its text is not publicly obtainable. What that profile does give you is the two operative requirements, and they happen to be the two a serious manufacturer can prepare for in advance. An application submitted to the regulator for the first time is handled as a new application, and medicines from a manufacturing facility the regulator has not previously inspected and approved must be accompanied by a Site Master File, with the regulator reserving the right to conduct a GMP inspection. That is a facility-level gate, not a paperwork gate, and it is the reason the practical order of work for Eritrea is inverted compared with most markets: prepare the Site Master File and the inspection readiness of the site first, then write to the regulator, and only then build the product dossier to whatever format the answer specifies. It is worth adding that Eritrea has neither signed nor ratified the African Medicines Agency treaty and does not appear on WHO's published list of regulators operating at maturity level 3 or 4, so there is no regional or reliance shortcut to substitute for that direct enquiry. Nor should anyone assume the neighbouring Ethiopian requirements apply: they are a different regulator under different law, and the substitution is the single most common error in published commentary about Eritrea. Quality Systems Behind Every Injectable Supplied to Eritrea When a regulator's published requirements are thin, the manufacturer's own quality system carries proportionally more of the burden of proof – and a Site Master File that may be tested by inspection is exactly the document that exposes whether that system is real. Farbe Firma manufactures under WHO-GMP certification in Gujarat, India, with aseptic filling in ISO Class 5 conditions, and maintains the full evidential chain behind every batch: assay and related substances by HPLC, residual solvents by GC, bacterial endotoxins by LAL, water content by Karl Fischer, container closure integrity, and media fills and environmental monitoring records that an inspector can follow from the room to the batch. Stability is generated under ICH Q1A(R2) and Q1B on conditions appropriate to the destination climate rather than adapted from temperate data, which matters for a Red Sea coastal supply chain. The second half of quality in a market like this one is documentary discipline about uncertainty. We will tell a customer for Eritrea exactly what we have verified and what we have not, in writing, and we will not manufacture a dossier to a format nobody has specified. Our files are maintained in CTD and ACTD structure and can be issued in either, with a WHO-format certificate of a pharmaceutical product, GMP certification, free sale documentation and per-product certificates of analysis available on request, so that whichever combination the regulator or PHARMECOR asks for can be produced quickly rather than assembled from scratch. Where a molecule is bound for a Global Fund or United Nations financed programme we can also discuss the additional documentation those channels typically expect, while being clear that we have not verified which procurement mechanism Eritrea's grants use. Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry Why Farbe Firma is the Trusted Injectable Manufacturer in Eritrea for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, exporting to more than 30 countries, and India is already a materially large supplier to this market. India's own reported exports of pharmaceutical products under HS Chapter 30 to Eritrea were about US$4.09 million in 2023, US$4.43 million in 2024 and US$3.40 million in 2025. Set against the Indian Ministry of External Affairs' figure of US$10.05 million for total Indian exports to Eritrea in the 2023-24 financial year, pharmaceuticals are roughly two-fifths of the entire bilateral export basket, and the Ministry names them first among goods exported. Eritrea does not report to UN Comtrade, so every one of those figures is India's own reported data rather than a two-sided reconciliation, and we present it as such. We are also realistic about how this market is entered. There is no distributor network to appoint and no tender portal to monitor: PHARMECOR is the documented importer and distributor, the Ministry of Health is the Principal Recipient on every Global Fund grant Eritrea has received since 2003, and the national regulator sits alongside PHARMECOR in the inspection process both before procurement and before items are released into service. That is a short list of counterparties, and it means the work is relationship and documentation rather than distribution build-out. It also means commercial terms deserve as much attention as technical ones, given a non-convertible currency, a government-set exchange rate and a central bank that must approve every transfer. We would rather have that conversation with a buyer at the quotation stage than discover it at the settlement stage, and we structure terms accordingly. What we bring to a market this thinly documented is manufacturing depth and candour in equal measure. More than 100 sterile injectable presentations across anti-infectives, analgesia and anaesthesia, oncology support, and critical-care and maternal-health molecules, filled on ISO Class 5 lines under WHO-GMP certification, with IP, USP, BP and EP monograph compliance and full CTD and ACTD dossier capability. Own-label and contract manufacturing are available for buyers who need product under their own brand. There is no India-Eritrea pharmaceutical or health memorandum of understanding – the Indian Ministry of External Affairs' own bilateral brief lists every instrument in force and none is in this sector – so nothing here rests on an intergovernmental arrangement. It rests on a manufacturer that can pass an inspection, document what it claims and say plainly what it does not know. To discuss a molecule, a tender line or a Site Master File submission, write to info@farbefirma.com. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) What does it take to register a medicine in Eritrea? Honestly, the requirements are not published. The only public description of the process states that an application submitted to the National Medicines and Food Administration for the first time is treated as a new application, and that medicines from manufacturing facilities not previously inspected and approved by the regulator must submit a Site Master File, with a GMP inspection possible. Whether a CTD or ACTD dossier is expected, whether a WHO certificate of a pharmaceutical product or a GMP certificate is mandatory, what samples or fees apply, how long review takes and how long an approval lasts are not stated in any source we could reach, and no Eritrean gazette or regulator website is available online. The practical first step is a written enquiry to the regulator, with your Site Master File already prepared. Who imports medicines into Eritrea? PHARMECOR, the Pharmaceutical and Medical Supplies Corporation of Eritrea, is the documented importer and distributor. Eritrean Ministry of Information reporting states that it distributed 351 million Nakfa of medicines and equipment in the first half of 2025, 85% to Ministry of Health facilities and 15% to other government institutions and private pharmacies, and 606 million Nakfa in 2023 on a 79/21 split; that it imported over US$32 million of supplies in 2023 and over US$8 million in the first half of 2025; and that technical, quality and financial inspections are conducted with the national regulator before procurement and again before items are put into service. Whether a private company may hold an import licence in its own right is not documented either way, so we do not assert that importation is legally monopolised – only that all documented importation runs through PHARMECOR. Is there local pharmaceutical manufacturing in Eritrea? There is some domestic production. PHARMECOR distributes 35 types of medicines produced by Azel Pharmaceutical Share Company, and Ministry of Information reporting groups Azel with an oxygen plant and an eyeglass enterprise when totalling domestic output. Beyond that we will not go: Azel's ownership, founding date, location, certifications and product range are described inconsistently across sources and we could not open the company's own site, so we do not assert whether Azel manufactures sterile injectables. Whether any sterile injectable is made in Eritrea at all is, for an exporter, the single most commercially relevant unknown, and it is genuinely unknown. How is medicine supply financed in Eritrea? Substantially through donor grants alongside the state. The Global Fund has financed ten grants since 2003 and the Ministry of Health is the Principal Recipient on all of them, with no separate United Nations or civil-society recipient. The three active grants cover HIV, tuberculosis and malaria with signed amounts of approximately US$117.3 million, US$28.8 million and US$87.6 million, all currently scheduled to end on 31 December 2026, and the next-cycle funding requests were submitted in May 2023. We have not verified the allocation for the next cycle or which procurement mechanism those grants use, so we do not state either. Domestically, health expenditure was estimated at US$28.30 per person in 2023, and the national budget is not published. What makes Farbe Firma a suitable injectable manufacturer for Eritrea? Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling on ISO Class 5 aseptic lines and exporting to more than 30 countries. For Eritrea specifically the decisive capability is inspection readiness: because the one published requirement is a Site Master File for previously uninspected sites with a possible GMP inspection, we maintain a current Site Master File and the supporting evidence behind it – HPLC and GC release testing, LAL endotoxin control, Karl Fischer moisture determination, media fills, environmental monitoring and ICH Q1A(R2) and Q1B stability generated on conditions appropriate to the destination climate. We prepare CTD and ACTD dossiers, can issue WHO-format certificates of a pharmaceutical product, GMP and free sale documentation on request, and offer own-label and contract manufacturing. Contact info@farbefirma.com to discuss a specific molecule, tender line or own-label programme. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 3, 2026 TL;DR: Gabon answers the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — with no list at all. The new Agence Nationale du Médicament et des Autres Produits de Santé, created by ordinance in October 2023 and given its statutes in January 2025, publishes a single dossier checklist for the Autorisation de Mise sur le Marché Gabonais and no reliance or abridged pathway; its guidelines page is empty and none of its thirty legal texts concerns recognition of foreign authorities. The CEMAC harmonisation regulation exists and the regional body OCEAC runs pilot joint evaluations, but no common authorisation is in force. The route is therefore the national one: a French-language CTD on USB, a GMP certificate under three years old for the finished-product site and for every active-ingredient site, fifty samples, a declared ex-factory price in CFA francs, a fee of 500,000 FCFA for an imported medicine, and a five-year authorisation. The commercial gate is the Office Pharmaceutique National, the state central purchasing body that supplies public hospitals and also private wholesalers, and the CNAMGS insurance fund, whose reimbursement rules were rewritten in 2025 and are still being contested. Key Takeaways No reliance list exists, so the origin-country file must be complete. The ANMAPS checklist asks for a copy of the country-of-origin authorisation with a certified French translation, a WHO-format certificate of a pharmaceutical product, the list of countries where the product is registered and, where it applies, WHO prequalification. Nothing conditions acceptance on the origin regulator being on a list, because there is no list; whether CDSCO would be treated as a reference authority is unknown in both directions. The dossier is French and electronic. Module 1 on paper and USB, Modules 2 to 5 in CTD format on USB only, the summary of product characteristics in French in editable form, a GMP certificate less than three years old for the finished-product manufacturer and each active-ingredient manufacturer, the manufacturing licence, the CVs of the heads of production and quality control, fifty commercial-pack samples with certificates of analysis, and an attestation of the ex-factory wholesale price in CFA francs. The instruments and fees are published; the timeline is not. The AMMG is valid for five years and a temporary commercial authorisation for two; the fee order of the Ministry of Health sets 500,000 FCFA for registration of an imported medicine, 350,000 for renewal, 100,000 for a major variation and 250,000 for a temporary authorisation. No statutory review period is published anywhere we could read, and we state none. The buyer is the State's central purchasing body and the insurance fund. The Office Pharmaceutique National buys under the public procurement code and supplies public hospitals, national programmes and private wholesalers from four bulk warehouses and nine regional depots. CNAMGS reimbursement was reset in March 2025 to 80%, 90% and 100% by category, with generics favoured over branded products, and the new reimbursable list was contested and suspended within months. Out-of-pocket spending is 17.3% of health expenditure, low for the region. Introduction: Why Gabon Demands a Premium Injectable Manufacturer in Gabon Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? Gabon is the clearest case yet of the answer being no list at any layer. The regulator is the Agence Nationale du Médicament et des Autres Produits de Santé, ANMAPS, an independent administrative authority under the Ministry of Health created by Ordinance No. 0004/PR/2023 of 24 October 2023, ratified by Law No. 006/2023 of 26 January 2024 and given its statutes by Decree No. 0091/PR/MS of 31 January 2025; it succeeds the former Direction du Médicament et de la Pharmacie and sits on the 2011 ordinance organising the pharmaceutical sector. Its website publishes one page on the registration of medicines, the homologation checklist for the Autorisation de Mise sur le Marché Gabonais, and that page contains no reliance route, no abridged procedure and no reference authorities. The guidelines section of the site is empty. Of the thirty legal texts the agency lists, only the order on variations and the order on fees concern the authorisation procedure, and neither names a foreign authority. The regional layer does not supply a list either. Gabon belongs to CEMAC, and Community Regulation No. 05/13 on the harmonised registration of medicines exists; we could not read its text. The regional health body OCEAC runs joint evaluation workshops under it — the Brazzaville session of December 2025 assessed fewer than fifteen dossiers selected through a call in August — and those are a pilot, not a route a company can plan around, so the national AMMG remains the operative gate. What the checklist does ask for is the origin-country authorisation with a certified French translation, a WHO-model certificate of a pharmaceutical product, the list of countries where the product is registered, and WHO prequalification where it applies. We therefore do not say that India is on or off any Gabonese list, because there is none; we say that a premium injectable manufacturer in Gabon is one whose Indian authorisation, CPP and GMP evidence are complete enough to stand on their own in French. What Sets a World-Class Injectable Manufacturer in Gabon Apart The dossier is French-language and electronic, and that settles more than it seems. The application is addressed to the Minister of Health through the Director-General of ANMAPS and signed by a responsible pharmacist; Module 1 goes in on paper and on USB, Modules 2 to 5 in CTD format on USB only, with the summary of product characteristics in French in an editable file and Module 5 carrying the biowaiver justification where a generic claims one. The checklist requires the certificate of opening of a pharmaceutical establishment for the authorisation holder, for the operating company and for the finished-product manufacturer, and a description of the commercial links between them. Whether the operating company must itself be established in Gabon is governed by an order on pharmaceutical establishments that we located but did not read, so we neither assert nor deny it; commercially, a Gabonese responsible pharmacist and importer are how the file is signed and how the product is sold. Fifty commercial-pack samples with certificates of analysis accompany a registration and thirty a renewal, and an attestation of the ex-factory wholesale price in CFA francs is part of the file, which means the price is declared before the product is authorised. The GMP requirement is stricter on paper than in many larger markets. The checklist wants a GMP certificate less than three years old for the finished-product manufacturer and for each manufacturer of an active ingredient, the manufacturing licence, the curricula vitae of the heads of production and quality control, and a copy of the notification of a favourable opinion for the laboratory visited — wording that implies an inspection step whose conditions and cost are not published, so we do not describe them. The instruments are clear: the AMMG is valid for five years and the temporary commercial authorisation, on the same dossier, for two. The fee order of the Ministry of Health, which we read as a scanned document, sets 500,000 FCFA for registration of an imported medicine against 300,000 for a locally made one, 350,000 for renewal of an imported product, 100,000 for a major and 50,000 for a minor variation, and 250,000 for a temporary authorisation. What is not published anywhere we could find is a review timeline, and the figures that circulate on consultancy sites are not something we repeat. The process is described as submission, expert analysis, commission, authorisation, and a supplier should plan for the commission calendar rather than a statutory clock. Quality Systems Behind Every Injectable Supplied to Gabon For a sterile injectable the evidence behind the GMP certificate is what will be tested if the laboratory-visit step is exercised: aseptic process simulation records for the ISO Class 5 filling line, environmental monitoring trends, container-closure integrity, sterility and bacterial endotoxin testing by LAL, particulate matter, validated HPLC and GC assay and impurity methods, and ICH Q1A stability generated for a hot and humid climate rather than extrapolated. Because the checklist also asks for the active-ingredient manufacturer's GMP certificate, the supplier must be able to produce its API supplier's certificate, under three years old, alongside its own — a detail that trips up manufacturers who treat the API file as somebody else's. Two further facts frame the file. Gabon does not appear on the WHO's August 2026 list of authorities operating at maturity level 3 or 4, which tells you only that it is not listed, not what its benchmarked level is; and it ratified the African Medicines Agency treaty in October 2021 as the fourteenth state to do so, while neither Gabon nor India is a PIC/S participating authority. ANMAPS announced ISO 9001 certification of its own management system in January 2026 and has been receiving evaluator training on bioequivalence and biosimilar dossiers through a French cooperation programme; a young agency building its assessment capacity is one that will ask more questions, not fewer, and the French-language quality of the answers will matter. Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry. Why Farbe Firma is the Trusted Injectable Manufacturer in Gabon for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries. We build dossiers in CTD and ACTD format and we are used to producing them in French for francophone Africa: Module 1 on paper and USB, Modules 2 to 5 electronic, the summary of product characteristics in editable French, the Indian authorisation with a certified translation, the WHO-format CPP, our own GMP certificate and our active-ingredient suppliers' certificates within three years, fifty samples with certificates of analysis and the ex-factory price attestation in CFA francs. Our analytical package of HPLC, GC, LAL, Karl Fischer and ICH Q1A/Q1B stability is written so that an expert analysis has nothing to return, and we say plainly that Gabon offers no reliance shortcut and that a complete national file is the whole strategy. The bilateral relationship is broad and the pharmaceutical trade is small but growing. India's Ministry of External Affairs brief of February 2025 records joint commission and foreign-service training agreements and an industry memorandum, and Gabon joined the Commonwealth in June 2022; pharmaceuticals were about USD 1.6 million and the sixth-ranked Indian export in 2023–24, far behind Gabon's mineral fuels, ores and timber flowing the other way, and we found no health or pharmaceutical memorandum and no cooperation between ANMAPS and CDSCO. UN Comtrade puts India-reported pharmaceutical exports to Gabon at USD 2.33 million in 2022, USD 2.12 million in 2023, USD 3.48 million in 2024 and USD 3.75 million in 2025, while Gabon reports imports of pharmaceutical products from India of USD 17.51 million in 2022 and USD 20.37 million in 2023. The two series differ by a factor of six to nine, which usually reflects goods of Indian origin arriving through European wholesalers; we report the gap and do not explain it. Where the money is: Gabon has 2.59 million people, gross national income per capita of USD 8,090 in 2025 — an upper-middle-income figure — current health expenditure of about USD 253 per person and 3.1% of GDP in 2023, and life expectancy of 68.5 years. Out-of-pocket payments were 17.3% of health expenditure in 2023, which is low for the region and reflects the insurance fund. The Office Pharmaceutique National, a state company created in 1995 and reorganised by ordinance in 2021, is the national central purchasing body: it buys under the public procurement code through international and restricted tenders, negotiated contracts and quotations, manages stock on an enterprise system, holds four bulk warehouses and one for the HIV and TB programmes, and supplies nine regional depots twice a year. Its clients are the university, regional and district hospitals, the health centres and national programmes, and also private wholesalers, polyclinics and NGOs; whether it is the mandatory supplier to public hospitals is not something we verified from a legal text, and we found no tender notices published. The CNAMGS fund's reimbursement was reset by ministerial order in March 2025 to 80% for common illnesses, 90% for long-term conditions and 100% for pregnant women, with generics by international non-proprietary name reimbursed at those rates and branded products at half; the accompanying list of reimbursable products was contested by pharmacies and suspended, and a ministerial meeting in November 2025 convened the fund, ANMAPS and the OPN to rebuild it. Tuberculosis incidence is high at 371 per 100,000, and the injectable demand is the general hospital formulary — antibiotics, anaesthetics, emergency, maternal and oncology medicines. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Is India on Gabon's list of recognised regulatory authorities? There is no list. The ANMAPS registration checklist contains no reliance or abridged pathway and names no reference authorities; its guidelines page is empty and none of its thirty legal texts concerns recognition of foreign regulators. The CEMAC harmonisation regulation exists but no common authorisation is in force. What Gabon asks for is the origin-country authorisation with a certified French translation, a WHO-format CPP, the list of countries where the product is registered and WHO prequalification where applicable. Whether CDSCO would be treated as a reference authority is unknown in both directions. What does a Gabonese marketing authorisation application require? An application to the Minister of Health through the ANMAPS Director-General, signed by a responsible pharmacist: Module 1 on paper and USB, Modules 2 to 5 in CTD format on USB in French, the SmPC in editable French, certificates of opening of a pharmaceutical establishment for the holder, the operating company and the manufacturer, a GMP certificate under three years old for the finished-product site and each API site, the manufacturing licence, CVs of the production and quality-control heads, fifty samples with certificates of analysis, the origin-country authorisation and CPP, and an ex-factory price attestation in CFA francs. What are the fees and how long is the authorisation valid? The Ministry of Health fee order sets 500,000 FCFA for registration of an imported medicine, 350,000 for renewal, 100,000 for a major variation, 50,000 for a minor one and 250,000 for a temporary commercial authorisation. The AMMG is valid for five years and the temporary authorisation for two. No statutory review period is published, and we do not state one. Can we use a CEMAC or regional registration to enter Gabon? Not in practice. Community Regulation No. 05/13 provides a harmonised framework and OCEAC runs pilot joint evaluations — the December 2025 session assessed fewer than fifteen dossiers — but no common CEMAC authorisation is in force and whether a joint evaluation leads automatically to a national AMMG is not established. Plan on the national procedure. How do we sell to the public sector in Gabon? Through the Office Pharmaceutique National, the state central purchasing body that procures under the public procurement code by international and restricted tenders, negotiated contracts and quotations, and supplies the public hospitals, health centres, national programmes and also private wholesalers from four bulk warehouses and nine regional depots. A Gabonese responsible pharmacist and importer are the practical partner. CNAMGS reimbursement rules were reset in 2025 and the reimbursable list is being rebuilt, so generic positioning by INN matters. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: August 27, 2026 TL;DR: Panama rewrote its medicines law in 2024 and a lot of the advice in circulation is now out of date. Ley 419 de 2024 replaced Ley 1 de 2001 and, unusually, regulates medicines and the public procurement of medicines in a single statute; Decreto Ejecutivo No. 27 de 10 de mayo de 2024 implements it. Registration sits with the Direccion Nacional de Farmacia y Drogas, is filed as a fully digital file, must be lodged by a Panamanian lawyer with a licensed pharmacist's endorsement and that of the national pharmacists' college, and runs either as a full procedure with prior laboratory testing or as an abbreviated one without it. A separate 2025 decree, as amended, adds automatic recognition for products registered by a WHO-Listed Authority – a route an Indian-registered product cannot use, which we say plainly. Farbe Firma Pvt Ltd fills sterile injectables on ISO Class 5 aseptic lines in a WHO-GMP certified facility in Gujarat, India, and builds the zone IVb stability and legalisation package a Panamanian distributor needs. Key Takeaways The law changed in 2024, and guidance written against Ley 1 de 2001 is stale. Ley 419 de 1 de febrero de 2024 subrogated the 2001 statute and merged medicines regulation with the public procurement of medicines into one instrument; Decreto Ejecutivo No. 27 de 10 de mayo de 2024, published in Gaceta Oficial 30028-C, is the operative regulation and runs to well over a hundred articles. Anything that describes Panamanian registration by reference to the 2001 law, or to the 2019 implementing decree, or to the Ministry's 2022 user guide with its paper dossier and folio numbering, is describing a regime that has been replaced by a digital one. Panama accepts authenticated copies and electronic apostilles for GMP evidence – the opposite of what is widely repeated. It is often said that Panama refuses certified copies and digital GMP certificates and insists on a physical legalised original. The current decree says otherwise. Article 28 allows the free-sale certificate in original or authenticated copy of the legalised document, or a WHO-type certificate of pharmaceutical product, and expressly includes the electronic apostille; Article 29 allows the GMP certificate in original or authenticated copy, and provides that where a regulator does not issue GMP certificates but maintains an electronic tool holding the complete manufacturer and GMP information, notarial copies of those official documents are accepted. Both certificates are treated as valid for two years unless the issuing authority says otherwise. The WHO-Listed Authority fast lane exists, and an Indian-registered product cannot use it. Decreto Ejecutivo No. 2 de 7 de enero de 2025, as amended, grants automatic recognition to human medicines manufactured and registered in countries whose regulator appears on the WHO-Listed Authority list, with no prior laboratory analysis, a response due within ten working days and a single round of observations answerable in five. India's CDSCO is not a WHO-Listed Authority, so a product resting on an Indian registration must use the ordinary procedure – with prior analytical testing – or the abbreviated procedure if the same product is registered and marketed under a high-standard authority. A supplier who implies otherwise is selling you a timeline that does not exist. Selling to the public system means selling through a Panamanian company. Ley 419 obliges the Ministry of Health and the Caja de Seguro Social to run joint purchases, held on the PanamaCompra portal, and the Ministry's national medicines director stated in March 2026 that the companies able to take part are those constituted in the country and authorised by the Direccion Nacional de Farmacia y Drogas. Every pharmaceutical establishment needs a two-year operating licence in its own category – droguería, agencia distribuidora, manufacturing or conditioning laboratory – and a permanently Panama-resident representative is required for registration. The manufacturer's job is to make that partner unbeatable on file quality; it is not to bid. Introduction: Why Panama Demands a Premium Injectable Manufacturer in Panama Panama runs two public health systems side by side, and that structure explains almost everything about how medicines are bought there. The Caja de Seguro Social protected 2,806,769 people in 2024, 62.2 per cent of the population on the national statistics institute's figures, and operates its own network of facilities; the Ministry of Health provides for those the Caja does not cover, through a separate network. Two buyers, two sets of facilities, two purchasing habits – which is precisely why Ley 419 de 2024 made joint purchasing a legal obligation rather than a good intention, and why the March 2026 joint exercise was framed around some 375 line items covering chronic-disease medicines, antibiotics and cancer treatments, with the Caja, the Ministry and the boards of the Hospital del Niño, the Hospital Santo Tomás and the Hospital José Domingo de Obaldía all buying together. The demand side has a clear injectable centre of gravity and a documented supply problem. The Caja's haemodialysis population rose from 2,277 patients in December 2024 to 2,438 by April 2026, better than seven per cent growth in sixteen months, with roughly four in five renal replacement patients on haemodialysis – a caseload that consumes heparin, iron, erythropoiesis-stimulating agents, antibiotics and infusion fluids continuously. Against that, the Caja publicly acknowledged shortages and activated emergency purchasing, an internal audit found expired stock across several storage points with investigations covering medicines and supplies worth more than US$2.5 million, and in September 2025 a commission for the evaluation of critical shortage was created by executive decree, bringing in the ombudsman, the medical association, the pharmacists' college and patient federations alongside the two buyers. Panama is not short of money for medicines. It is short of reliable delivery. What Sets a World-Class Injectable Manufacturer in Panama Apart The first differentiator is knowing which of the three registration routes applies to you and not overpromising the fast one. Decreto Ejecutivo No. 27 provides an ordinary procedure with full technical and analytical evaluation, in which prior laboratory testing at the Instituto Especializado de Análisis is required and paid for separately, and an abbreviated procedure for medicines already registered and marketed in countries whose regulators are recognised as high-standard, in which Article 21 dispenses with prior analytical testing. On top of those sits the 2025 automatic-recognition decree for WHO-Listed Authority registrations. The honest position for an Indian manufacturer is that the third route is closed on an Indian registration alone, the second depends on whether the same product carries a high-standard-authority registration, and the first is the one to plan and resource for. The second is treating the filing chain as part of the technical package. An application must be lodged through the digital platform by a Panamanian lawyer, carry the endorsement of a licensed pharmacist as technical responsible and the endorsement of the Colegio Nacional de Farmacéuticos, and be supported by a notarised power of attorney from the holder or manufacturer; dossier documents must be in Spanish, with foreign-language material translated by an authorised public interpreter, though clinical studies may be filed in English with a Spanish benefit-risk summary and certificates of analysis in either language. Deficiencies carry a three-month window, and missing it does not pause the file – it returns it, and the applicant starts a wholly new application and loses the original case numbers. A manufacturer who supplies clean, correctly legalised, correctly translated documents the first time is protecting the distributor from a restart. Quality Systems Behind Every Injectable Supplied to Panama Farbe Firma fills sterile injectables on ISO Class 5 aseptic lines inside a WHO-GMP certified facility in Gujarat, India, with environmental monitoring, media fills, operator qualification, filter integrity and container-closure integrity testing run as a continuous programme. Release testing is performed against IP, USP, BP and EP monographs using HPLC and GC for assay and related substances, Karl Fischer where the presentation requires it, and LAL for bacterial endotoxins, with sterility testing on every sterile lot. Panama makes particular use of this at the border: biological products may not be imported or marketed without the batch certificate of analysis in original or authenticated copy signed by the manufacturer's quality assurance head, vaccines and homologous blood derivatives require lot-by-lot release authorised by the National Director, and heparin sodium products require certificates of analysis for both the active and the finished product together with a proton NMR test on the manufactured active lot. Stability is the point where Panama is unforgiving, and it is specific. Panama is climatic zone IVb – hot and very humid – and says so expressly in the 2025 recognition decree, with stability studies following the Central American technical regulation on stability that Panama adopted by Decreto Ejecutivo No. 850 de 4 de agosto de 2015. We generate ICH Q1A(R2) long-term and accelerated data with photostability under ICH Q1B in the actual container-closure system that will ship, on zone IVb conditions rather than on temperate data borrowed from a European or North American file. A GMP certificate is required for every establishment involved in manufacture, and separately for the conditioner where packing happens elsewhere, so our site documentation is maintained per-site and legalisation-ready rather than assembled at the point of need. Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry Why Farbe Firma is the Trusted Injectable Manufacturer in Panama for Global Buyers Panama's Central American regulatory layer is real, but it is Panama's own, and this matters because it is easy to assume that a neighbour's rules transfer. Panama gave effect to the current Central American technical regulation on sanitary registration by Resolución No. 126 de 16 de julio de 2021, and adopted the regulations on pharmaceutical labelling, stability studies and analytical method validation by its own executive decrees 849, 850 and 851, all of 4 August 2015. Decreto Ejecutivo No. 27 then hard-wires those instruments into current practice, requiring registration to comply both with the statute and with the Central American technical regulations adopted by the Direccion Nacional de Farmacia y Drogas, and governing renewal by reference to them. Registration validity runs five years on that basis. What we will not tell you is that a Panamanian registration travels to another Central American country, because we have not verified that it does. There are two structural openings a manufacturer should know about. The first is the second-distributor route: a distributor other than the registered one may import an identical product under a certification of importation under a valid sanitary registration, supported by the manufacturer's attestation of lawful manufacture to approved specifications, a certificate of pharmaceutical product or free-sale certificate with a GMP certificate, original samples, Spanish primary and secondary labelling and an establishment licence – with the first batch subject to prior control and not marketable until analytical results are presented. The second is the Colón Free Zone, where the decree exempts foreign companies with no physical presence in the zone that operate for re-export only under a special represented-company key, working through a representing user company that must itself hold an operating licence from the Direccion Nacional de Farmacia y Drogas. That is the lawful structure for using Panama as a regional hub. Farbe Firma Pvt Ltd works as both manufacturer and CDMO, which fits a market where the same molecule may need to serve a joint public tender line and a private distributor's own-label presentation simultaneously. We supply dry powder vials, liquid ampoules and vials, lyophilised presentations and small-volume parenterals across anti-infectives, analgesia, anaesthesia, oncology support, nephrology and critical care; we run own-label and technology-transfer programmes; and we prepare CTD and ACTD dossiers, DMF and CEP-referenced active-substance documentation and apostilled certification for more than 30 export markets. For a Panamanian droguería or agencia distribuidora the practical offer is a manufacturer whose zone IVb stability, per-site GMP documentation and Spanish-ready artwork arrive complete, so the three-month deficiency window never becomes a restart. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Who regulates medicines and injectables in Panama, and under what law? The Dirección Nacional de Farmacia y Drogas of the Ministerio de Salud. It issues, suspends, modifies, renews and cancels the sanitary registration and runs pharmacovigilance, pre-market and post-market control and the inspection of establishments, and it has statutory power to certify Good Manufacturing Practice following audit. The governing statute is Ley 419 de 1 de febrero de 2024, which subrogated Ley 1 de 10 de enero de 2001 and which regulates both medicines and the public procurement of medicines; the implementing regulation is Decreto Ejecutivo No. 27 de 10 de mayo de 2024, published in Gaceta Oficial Digital No. 30028-C. Filing is fully digital through the authority's platform. Does Panama accept a digital or copied GMP certificate, or must it be a legalised original? The current decree accepts more than is commonly claimed. The free-sale certificate may be presented in original or in authenticated copy of the legalised document, or replaced by a WHO-type certificate of pharmaceutical product, and the text expressly includes the electronic apostille; no more than two years may separate issue and filing unless the issuing authority states a different validity. The GMP certificate may likewise be presented in original or authenticated copy, and where the regulator does not issue such certificates but maintains an electronic tool containing the complete manufacturer and GMP information, notarial copies of those official documents are accepted. A separate GMP certificate is needed for each establishment involved in manufacture, and for the conditioner if packing occurs in another country. India is a party to the Apostille Convention, so apostille is the practical authentication route from an Indian site. Can an Indian-manufactured injectable use Panama's automatic recognition route? Not on an Indian registration. The 2025 decree, as amended, grants automatic recognition only where the medicine is manufactured and registered in a country whose regulator is on the WHO-Listed Authority list, and India's CDSCO is not on that list. The route requires a legalised power of attorney to a person permanently resident in Panama, a certificate of pharmaceutical product in original, legalised or apostilled form with GMP compliance annexed for every manufacturing site, a legalised or apostilled copy of the complete dossier as filed in the country of registration, and zone IVb stability studies; the authority then responds within ten working days with one round of observations. An Indian site should plan for the ordinary procedure, which includes prior analytical testing, unless the same product also carries a high-standard-authority registration that opens the abbreviated route. How does an Indian manufacturer sell into Panama's public health system? Through a Panamanian partner, not directly. Joint purchases by the Ministry of Health and the Caja de Seguro Social are held on the PanamaCompra portal, and the Ministry's national director of medicines and supplies stated in March 2026 that participation is open to companies constituted in the country and authorised by the Dirección Nacional de Farmacia y Drogas. That partner must hold an operating licence in the right category – a droguería for import and wholesale of pharmaceutical products, or an agencia distribuidora for import, storage, distribution and transport – renewed every two years. Import itself requires an authorisation, a valid registration or an importation certification under a valid registration, a customs pre-declaration, a compliant invoice and a cargo manifest. For scale reference, the joint call published in October 2024 covered 220 line items at a reference price of about US$124.4 million. What makes Farbe Firma a suitable injectable manufacturer for Panama? Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling on ISO Class 5 aseptic lines and exporting to more than 30 countries. For Panama specifically we generate ICH Q1A(R2) and Q1B stability on climatic zone IVb conditions rather than adapting temperate data, maintain per-site and per-conditioner GMP documentation in a form that authenticates cleanly by apostille, issue batch certificates of analysis signed by the quality assurance head in the form the import rules require for biological products, and can supply active and finished-product certificates plus proton NMR data where heparin sodium is involved. We work to IP, USP, BP and EP monographs, prepare CTD and ACTD dossiers, and provide Spanish-ready artwork and insert content so the translation and legalisation chain does not become the reason a file is returned. Contact info@farbefirma.com to discuss a specific molecule, tender line or own-label programme. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: August 31, 2026 TL;DR: Qatar is the first market in several we have written up where the answer to the standing question is genuinely favourable. We read the Pharmacy and Drug Control Department’s eCTD submission guidance in full and searched it for reference-country language: there is no reference-country list, no list of recognised regulators whose GMP certificates are accepted, and no eligibility gate keyed to ICH membership. The clauses requiring a GMP certificate for every manufacturing site and for all active ingredient suppliers, and a certificate of pharmaceutical product, do not name permitted issuing countries. An Indian WHO-GMP certificate is admissible on its face, subject to a legalisation chain through the issuing authority, the Ministry of External Affairs and the Qatari embassy. The gates are elsewhere and they are real: a licensed Qatari agent is the only party the ministry will deal with, GCC central registration is a review discount rather than a passport, and the price certificate must disclose your CIF price for other GCC countries alongside the Qatari one. On a market of under three million people, that last point is the one that should drive your sequencing. Key Takeaways Qatar does not operate a reference-country or recognised-issuer list. We read the Pharmacy and Drug Control Department guidance on eCTD submission in full and keyword-scanned it for reference-country, recognised-country, country-of-origin and basket language. Section 1.7.1 requires an original, valid and legalised GMP certificate for any manufacturing site involved in any step of finished product manufacture plus valid GMP certificates for all active ingredient suppliers, and section 1.7.2 requires a certificate of pharmaceutical product. Neither names permitted issuing countries. The only references to ICH in the document are to its technical specifications as the basis of the eCTD format, not to membership as an eligibility test, so the Member-versus-Observer trap that closes some markets to an Indian file does not arise here. This finding is scoped to the instrument we read. GCC central registration does not give you Qatar. The department’s own text is explicit: it allows fast-track assessment of products already registered centrally by the GCC and exempts them from full assessment, but full data requirements must still be submitted as an ordinary new-registration submission, and it reserves the right to treat the file as an ordinary submission and disregard the central registration whenever it deems it necessary. You must supply the valid GCC registration certificate stamped by the GCC Executive Office together with all post-registration variation approvals, and declare that the product information is identical to that approved centrally. Anyone who tells you one GCC filing yields six national licences is wrong about Qatar. You cannot be your own registrant, and the agent is a substantive gatekeeper. The guidance states that the local agent is responsible for the product in Qatar and is the only body authorised to deal with the ministry under Qatari law. Any Qatari organisation may register itself as an agent after meeting the requirements, which include a registration certificate for agents of pharmaceutical factories and companies, a valid drug store licence, a valid pharmacist licence from the Qatar Council for Healthcare Practitioners, a commercial register entry with the appropriate activity, and a store licence. Agent registration itself carries no fee. Note the sequencing: the agent, the marketing authorisation holder and every manufacturing site must all be registered before any product application can be filed. The pricing rule is the commercial centre of the decision. Module 1.8.1 requires a legalised price certificate stating ex-factory, wholesale and CIF prices for Qatar in US dollars along with CIF prices for other GCC countries, so your Qatari price is assessed against your regional prices at the moment of filing. The GCC Health Council states that its Gulf Committee for Pricing of Pharmaceuticals unifies the agent and pharmacy margin across member states at not more than forty-five per cent, and unifies the prices of centrally and peripherally registered medicines at each five-yearly re-registration. On a market the World Bank sized at 2,857,822 people in 2024, the question is less whether you can register in Qatar than whether you can afford to set a regional price anchor there. Introduction: Why Qatar Demands a Premium Injectable Manufacturer in Qatar For several markets in this series the first research question has produced the same disappointing answer. A country advertises a fast, well-documented reliance or recognition pathway; you read the instrument that names the eligible regulators; India is not on the list. It has been true often enough that we now ask the question before anything else. Qatar is the market where the answer came back the other way, and it is worth stating carefully because the distinction matters. We obtained the Pharmacy and Drug Control Department’s guidance on eCTD submission, the primary instrument governing registration filings, and searched the complete text for reference-country language, recognised-regulator language, country-of-origin restrictions and pricing baskets. There is no such list. Section 1.7.1 requires an original, valid and legalised good manufacturing practice certificate for any manufacturing site involved in any step of the finished product process, together with valid certificates for all active ingredient suppliers, and section 1.7.2 requires a certificate of pharmaceutical product. Neither clause restricts which national authority may issue them. The only mentions of ICH in the document are to its technical specifications as the basis of the electronic format, not to membership as a qualification, which means the trap that catches Indian filers in markets gating on ICH membership — India’s CDSCO is an Observer, not a Member — simply does not arise on the face of this instrument. Two qualifications belong with that finding rather than in a footnote. First, it is scoped to the document we actually read. The guidance cross-references the GCC Data Requirements for Human Drugs Submission and the GCC Module 1 specifications, which we did not obtain; a country restriction could in principle live in one of those, and we are not claiming otherwise. Second, the ministry’s website sits behind bot protection and could not be browsed, so while we read the guidance in full we could not confirm whether a newer version exists. The file is served under a filename bearing 2023 while its title page reads version 1.0 of July 2019, and we could not resolve that discrepancy. Ask the department for the current version before you build a file against it. What replaces a country list, in practice, is a documentary chain: authentication by the health authority and the ministry of foreign affairs in the country of origin, followed by the Qatari embassy or consulate where the document was issued. For an Indian manufacturer that means a CDSCO or state authority certificate, legalised through the Ministry of External Affairs and then through the Embassy of Qatar in India. It is a real administrative burden with a real lead time, but it is a burden that can be discharged, which is a materially different position from being ineligible. What Sets a World-Class Injectable Manufacturer in Qatar Apart The mechanics reward precision. Electronic common technical document format is mandatory for registration, re-registration and variation applications for human medicines, built on GCC CTD content and validated against the GCC validation specifications, with applications filed through the department’s electronic services portal. A physical submission still accompanies it, and the detail is unusually prescriptive: an in-person appointment, two DVDs burned with a closed session and no password protection or file-level security, an MD5 checksum and a validation report, and a bound hard-copy Module 1 volume in a colour-coded folder — black for a new registration, red for a fast-track new registration, grey for a variation, yellow for a fast-track variation and green for a renewal. Module 1 must carry original company paper with authorised signature and company stamp, and includes the cover letter, application form, physical samples and reference standards with certificates of analysis, the legalised GMP certificate and certificate of pharmaceutical product, alcohol-free and pork-free declarations, a statement on diluents and colouring agents, patent information, a drug master file letter of access, and the legalised price certificate. Patient information leaflets must be provided in both Arabic and English; other documents are in English or officially translated. The clocks in this system run against the applicant rather than the regulator, and that asymmetry deserves emphasis because it is where files die. At the deficiency stage the applicant has four months to answer comments, and failure means rejection with the file returned. At committee stage there is a further four months, and failure there means automatic deletion, after which the product must be resubmitted as an entirely new application. Registration is valid for five years; a renewal may be requested once the certificate expires and up to six months after the end of the five-year period, and miss that window and the registration is cancelled automatically, requiring a full new electronic file. Fast-track handling is available on written justified request, but written approval must be obtained before the file is submitted and attached to it, which is a sequencing point that is easy to get wrong. What the instrument conspicuously does not contain is any assessment timeline binding the department itself. We looked for one and there is none, so we will not repeat the six-to-twelve month figures that circulate in consultancy summaries. Nor will we quote fees: the only fee we verified is that agent registration is free. Product, renewal, variation and central registration fees are unknown to us and we would rather leave a gap than fill it with an estimate. Quality Systems Behind Every Injectable Supplied to Qatar On mutual recognition the position is symmetrical and worth stating plainly, because it removes a false hope in both directions. We checked all four official PIC/S lists — participating authorities, applicants, pre-applicants and former pre-applicants — and neither Qatar nor India appears on any of them. Within the Gulf Cooperation Council only Saudi Arabia’s authority is a participating authority, having acceded in July 2023, while the United Arab Emirates sits among the pre-applicants. So there is no PIC/S-based reliance route into Qatar, and India could not use one if there were. On the World Health Organization’s listed authority and maturity-level registers we have to report a gap rather than a finding: the relevant pages returned errors or empty responses when we tried to read them, so we make no claim about Qatar’s status in either direction, and no reader should infer absence from our silence. The GCC Health Council does describe factory inspection to verify good manufacturing practice as a function of its central drug registration committee, and standardising factory inspection to international norms as a programme aim, but whether an Indian plant can be or has been inspected and listed under that mechanism, at what cost and on what queue, we could not establish. The market’s shape matters more than its size here, and two structural facts do most of the work. The first is that this is an institutionally financed system: the World Bank puts out-of-pocket spending at 7.43 per cent of current health expenditure in 2023, against current health expenditure of USD 1,804.35 per capita and only 2.52 per cent of gross domestic product. Both of those last two are true at once because national income is very high — gross national income per capita was USD 76,570 in 2024 — so per capita spending, not the share of output, is the relevant sizing metric. For injectables the practical consequence is that the buyer is the state hospital system and retail pharmacy strategy is close to irrelevant. We should be equally clear that hospital procurement is the area we researched least: we did not obtain the tender rules of the principal public providers, the mechanics of Gulf joint procurement, prequalification criteria or local content requirements, and in a market financed this way that is the most commercially important gap in this article. The second structural fact is demographic. Qatar’s population is majority non-national with a heavy young male labour skew, and the denominators disagree: the World Bank records 2,857,822 for 2024 while the World Health Organization’s tuberculosis estimates use 3,048,426 for the same period, a difference of roughly 190,000. Prevalence rates imported from regional averages will misstate the real patient mix. Tuberculosis incidence was 37 per 100,000 in 2024, about 1,100 cases with around nine deaths, which in a country with life expectancy of 82.52 years is a screening-detected and largely expatriate pattern rather than an endemic one. We obtained no oncology, diabetes or dialysis figures for Qatar and therefore give none. Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry Why Farbe Firma is the Trusted Injectable Manufacturer in Qatar for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty markets. We produce dry powder and liquid vials, ampoules and lyophilised presentations, with analytical control resting on HPLC, GC, Karl Fischer titration and LAL bacterial endotoxin testing, and stability programmes designed to ICH Q1A and Q1B. We compile dossiers in CTD, ACTD and eCTD formats and maintain drug master files where they are required. For Qatar that base position is directly usable rather than merely respectable, because the department’s document requirements are issuer-agnostic: what it asks for is a valid, original, legalised GMP certificate covering every site involved in any step, certificates for all active ingredient suppliers, and a certificate of pharmaceutical product. Those we can produce and legalise. Where we add most value is in the parts of a Qatari file that are easy to underestimate. The legalisation chain is a lead-time item, not a signature: each document passes through the issuing health authority, then the Ministry of External Affairs, then the Embassy of Qatar, and a file assembled without planning for that will sit idle. The electronic submission has hard technical acceptance criteria — GCC validation specifications, an MD5 checksum, a validation report, closed-session media without security settings — and a file that fails validation has not been filed. The prerequisite sequencing catches newcomers repeatedly: your agent, your marketing authorisation holder and every manufacturing site must be registered with the department before a product application can be lodged at all, so the critical path starts months before the dossier is ready. And because the applicant-side clocks are unforgiving, with four months at deficiency stage and four at committee stage and automatic deletion on failure, responsiveness is a regulatory control rather than a courtesy. We staff files accordingly. The last thing we would put to a buyer is the commercial sequencing question, because it is the one most likely to be decided by accident. Qatar requires you to disclose, at filing, your CIF price for other Gulf Cooperation Council countries alongside the Qatari one, and the GCC Health Council’s pricing committee describes its own mandate as unifying prices across member states, capping the combined agent and pharmacy margin at forty-five per cent, and re-unifying prices of both centrally and peripherally registered medicines at each five-year re-registration. Read those together and a Qatari price is not a local decision. It becomes a regional anchor, and it is re-tested downward every five years. Against a population under three million and total Indian pharmaceutical trade with Qatar that United Nations Comtrade puts at around USD 10.9 million on India’s own 2024 figures — with Qatar reporting USD 17.3 million for the same year, a mirror gap of roughly fifty-nine per cent that we can report but not explain — this is a small absolute market carrying a large pricing consequence. Our advice is not that Qatar should be avoided. It is that Qatar is a follower market, best entered once your prices in the larger Gulf economies are set, and that the bilateral relationship offers no shortcut: the Indian Ministry of External Affairs brief records a 2016 health cooperation memorandum and a first joint working group meeting in December 2021 that discussed pharmaceutical cooperation, but no pharmacopoeia recognition, no GMP mutual recognition and no registration reliance agreement. Registration is open; pricing is the decision. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Does Qatar require our GMP certificate to come from a specific country? Not on the face of the instrument we read. The Pharmacy and Drug Control Department’s eCTD submission guidance requires an original, valid and legalised GMP certificate for any manufacturing site involved in any step of finished product manufacture, plus valid certificates for all active ingredient suppliers, and separately a certificate of pharmaceutical product. Neither clause names permitted issuing countries, and the only ICH references in the document are to technical format specifications rather than to membership as an eligibility test. An Indian WHO-GMP certificate is therefore admissible on its face. Two caveats: our finding is scoped to that document, and the guidance cross-references GCC data requirements that we did not obtain. Does GCC central registration mean one approval for all six countries? No, and this is the most commonly repeated error about the region. Qatar’s own text says the department allows fast-track assessment of centrally registered products and exempts them from full assessment, but that full data requirements must still be submitted as an ordinary new-registration submission, and that it may treat the file as an ordinary submission and disregard the central registration whenever it deems necessary. You must also file the GCC registration certificate stamped by the GCC Executive Office with all variation approvals, and declare the product information identical to that centrally approved. Central registration is a review-burden discount inside a mandatory separate national registration. Can we hold the registration ourselves as the manufacturer? No. The guidance states that the local agent is responsible for the product in Qatar and is the only body authorised to deal with the ministry under Qatari law, with the department reserving only a discretionary right to communicate with the licence holder in certain cases. Module 1.9 requires an original legalised authorisation letter from the marketing authorisation holder appointing the applicant and stating explicitly that it will act as product agent in Qatar under Qatari law. The agent must hold a certificate for agents of pharmaceutical factories and companies, a drug store licence, a pharmacist licence from the Qatar Council for Healthcare Practitioners, an appropriate commercial register entry and a store licence. Agent registration itself is free of charge. How long does Qatari registration take and what does it cost? We cannot tell you, and we would rather say that than repeat a number we cannot source. The instrument sets out only the applicant’s own deadlines — four months to respond at deficiency stage, with rejection on failure, and four months at committee stage, with automatic deletion and the need to resubmit as a new application. It contains no assessment timeline binding the department. Any six-to-twelve month or eighteen-month figure you encounter is a consultancy estimate rather than a published commitment. On fees, the only one we verified is that agent registration is free; product, renewal, variation and central registration fees we did not obtain. Is Qatar commercially attractive for an Indian injectable exporter? It is open, but it should be sequenced late rather than used as a pilot. The market is small in absolute terms — the World Bank recorded 2,857,822 people in 2024 — and almost entirely institutionally financed, with out-of-pocket spending at 7.43 per cent of health expenditure in 2023, so the state hospital system is the buyer. Indian pharmaceutical exports to Qatar were about USD 10.9 million on India’s 2024 Comtrade figures, against USD 17.3 million reported by Qatar, a gap we report without explaining. The decisive factor is pricing: your filing must disclose CIF prices for other GCC countries, and the Gulf pricing committee unifies prices across member states and re-unifies them at each five-yearly re-registration, with agent and pharmacy margin capped at forty-five per cent. A price set in Qatar propagates. Enter after your larger Gulf prices are settled. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: August 26, 2026 TL;DR: Kuwait is the Gulf market where price and partner are the same decision, and both are close to irreversible. Medicines are registered by the Pharmaceutical and Herbal Medicines Registration and Control Administration of the Ministry of Health, under Ministerial Decree No. 302/1980 as updated by Ministerial Decree No. 361 of 2019, in a two-stage sequence: the Kuwaiti agent is qualified first, then the marketing authorisation holder and each manufacturing site, then the product dossier in CTD structure. The agent letter must name a sole and exclusive agent in the State of Kuwait, with no exception – even though Kuwait's own commercial agencies law of 2016 removed exclusivity for ordinary goods. Meanwhile the Ministry openly prices medicines to be the cheapest in the Gulf, publishes them in a public database and enforces those prices on companies and distributors. Farbe Firma Pvt Ltd fills sterile injectables on ISO Class 5 aseptic lines in a WHO-GMP certified facility in Gujarat, India, and supplies the Site Master File and certificate package a Kuwaiti agent needs to open and defend a file. Key Takeaways Your Kuwaiti price is a Gulf-wide decision, not a Kuwaiti one. Kuwait's Ministry of Health prices to Gulf and international reference benchmarks and states explicitly that the result should be among the cheapest in the Gulf region. In October 2025 the Minister of Health approved and priced 392 new products selected from 1,580 reviewed over the preceding year on that basis, and in May 2026 the Ministry reduced prices on around 1,922 medicines, preparations and supplements while approving and pricing 268 new ones. Prices are published in a public Ministry database and the October 2025 directives include enforcing adherence to the set price by companies and distributors. A concession made in Kuwait does not stay in Kuwait: it becomes a reference point for neighbouring regulators. One exclusive agent, by law, with no exception – and the two Kuwaiti laws do not agree. Kuwait's Commercial Agencies Law No. 13 of 2016 removed the exclusivity requirement for commercial agencies generally, and foreign firms may now register multiple agents. But the Ministry of Health's registration requirements demand an original legalised letter appointing a sole and exclusive agent in the State of Kuwait, and regional counsel describe that requirement as admitting no exception. The agency agreement must also be registered with the Ministry of Commerce and Industry, because an unregistered agreement will not be heard by the Kuwaiti courts. Choose the agent as carefully as you would choose a joint venture partner. The Site Master File ask is unusually deep, and that is an opportunity. Registering a manufacturing site in Kuwait calls for an original legalised manufacturing licence and an original legalised GMP certificate from the health authority of the country of origin, together with a Site Master File covering company history, capital and turnover for the past three years, site layouts, the quality control unit, personnel numbers and qualifications, premises and equipment, the product list and export countries, worldwide complaints, defects and recalls, and contract manufacturing arrangements, plus a Pharmacovigilance Master File. The Administration may also require a GMP inspection visit to any site. A manufacturer with a clean, complete and current record turns that transparency requirement into a differentiator. Public demand is concentrated, institutional and injectable-heavy. Kuwait's public healthcare sector accounts for more than 80% of national healthcare spending, and the Ministry of Health is owner, operator, regulator and financer of the majority of services and of the pharmaceuticals purchased, running 28 general and specialised hospitals and more than a hundred polyclinics, with distribution through Central Medical Stores. Published clinical data records 2,230 patients on dialysis in 2019 at a prevalence of 465 per million population, of whom 59% had diabetes, while the Kuwait Cancer Control Center is a 200-bed complex with more than 600 oncology staff treating over 2,000 new cancer patients a year. Those are precisely the categories that consume sterile small-volume parenterals. Introduction: Why Kuwait Demands a Premium Injectable Manufacturer in Kuwait Kuwait registers medicines through the Pharmaceutical and Herbal Medicines Registration and Control Administration of the Ministry of Health, the department named in Ministerial Decree No. 361 of 2019, which updates and supplements the original registration guidelines issued under Ministerial Decree No. 302/1980. Drug and Food Control remains the operational contact function within the Ministry. The sequence is strict and it is worth learning in order, because filing out of order wastes months. First the Kuwaiti company that will act as agent is qualified, with a Ministry of Commerce licence covering the sale of medicines, a licence and a store licence from the Drug Inspection Administration, and authorised signatures legalised by the Kuwait Chamber of Commerce and Industry. Then the marketing authorisation holder and each manufacturing site are registered. Only then does the product dossier follow, in CTD structure per Gulf guidelines, with a Kuwait-specific Module 1. Two features then shape everything commercial. The first is that registration is valid for five years with the renewal file due six months before expiry, and that labelling and the patient information leaflet must be bilingual in Arabic and English. The second is pricing. Kuwait does not merely reference-price quietly; the Ministry says publicly and repeatedly that it intends Kuwaiti prices to be the lowest in the Gulf, it acts on that several times a year, and it publishes the resulting prices in a public database. Choosing an injectable manufacturer in Kuwait's supply chain therefore means choosing one that can hold a specification and a cost base at a Gulf-benchmarked price over a five-year registration cycle, through a single exclusive agent, without quality drift. What Sets a World-Class Injectable Manufacturer in Kuwait Apart The first differentiator is understanding the exclusivity trap before signing anything. Kuwait presents a genuine conflict between two of its own regimes. The Commercial Agencies Law No. 13 of 2016 replaced the 1964 law and removed the exclusivity requirement, and the United States International Trade Administration's commercial guide confirms that foreign firms may now register multiple agents. The Ministry of Health, however, requires a legalised letter of authorisation naming a sole and exclusive agent in the State of Kuwait as a mandatory registration document, and regional counsel are explicit that there is no exception to it – the rationale being a single accountable party for record-keeping, pharmacovigilance and recalls. Kuwaiti law then favours the agent, with protections including compensation on non-renewal attaching where a relationship is exclusive or effectively exclusive. Changing agent later requires a legalised appointment letter for the new agent, a termination letter from the marketing authorisation holder stating the termination date, and a list of every affected product by name, strength, dosage form and manufacturer. The second is disciplined documentation, because Kuwait asks for depth rather than volume. The manufacturing licence and the GMP certificate must be originals legalised by the health authority of the country of origin, and counsel advise that the GMP certificate should have been issued within the previous two years. The Site Master File goes well beyond a plant description into three years of capital and turnover figures and a worldwide history of complaints, defects and recalls, and a Pharmacovigilance Master File sits alongside it. The Administration may require a GMP inspection visit to any manufacturing site named in the file. From India, commercial and regulatory documents typically travel through a chamber of commerce, then the Ministry of External Affairs, then the Embassy of Kuwait, and a manufacturer who plans that chain into the schedule rather than discovering it will save a submission cycle. Biological and biosimilar products carry an additional Kuwaiti condition: they must satisfy Gulf Health Council provisions and be registered with a competent reference authority such as the United States Food and Drug Administration or the European Medicines Agency. Quality Systems Behind Every Sterile Injectable Farbe Firma fills sterile injectables on ISO Class 5 aseptic lines inside a WHO-GMP certified facility in Gujarat, India. Sterility assurance is designed into the process rather than inferred from a final test: terminal sterilisation or aseptic processing is selected on the product's own merits and supported by media fill validation, routine environmental and personnel monitoring, container closure integrity testing and a documented contamination control strategy. Release testing runs on HPLC and GC for assay and related substances, LAL for bacterial endotoxins, Karl Fischer for water content where the presentation calls for it, and full compendial sterility testing against IP, USP, BP and EP monographs. Because the Kuwaiti file names the site and invites inspection of it, the plant documentation – layouts, utilities, personnel qualification records, the quality control unit and its instrument qualification history – is maintained in an inspection-ready state rather than assembled when a request arrives. Stability is generated to ICH Q1A(R2) with photostability under ICH Q1B, in the container-closure system that will actually ship, and defended on hot and humid conditions appropriate to Gulf storage and transit rather than on temperate data. Dossiers are compiled in CTD structure with the regional module built to the requirements of the receiving authority. Artwork and package inserts are produced bilingually in Arabic and English as Kuwaiti requirements demand, in editable form so that an agent can respond to a labelling query without waiting on a new production cycle; and because Kuwaiti practice expects the mark to appear in Arabic on the pack or the leaflet, Arabic-script brand artwork is prepared alongside the Latin-script version from the outset rather than retrofitted. Certificates that must travel through legalisation are issued in a form that survives the chamber, ministry and embassy chain without a reissue. Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry Why Farbe Firma is the Trusted Injectable Manufacturer in Kuwait for Global Buyers The demand picture in Kuwait is unusually easy to read because the public sector dominates it. More than 80% of healthcare spending is public, and the Ministry of Health is simultaneously the owner, operator, regulator and financer of most services and of the pharmaceuticals purchased, running 28 general and specialised hospitals and over a hundred polyclinics, with public-sector medicines distributed to health centres from Central Medical Stores. Tendering runs through the Central Agency for Public Tenders on behalf of ministries and through the Ministry's own electronic tenders portal, which operates its own supplier company registration. Government procurement is conducted with Kuwaiti citizens and firms, so in practice a foreign manufacturer competes through its Kuwaiti agent, using the manufacturer's documentation. Under the national development programme the government has set out plans to raise bed capacity by roughly 40% over five years, from 8,757 to 12,230 beds, with pharmaceuticals named as a best-prospect sector. The clinical demand behind that spending is concentrated in the categories that consume injectables. Kuwait has among the highest age-standardised diabetes prevalence in the world, and the consequences are visible in the renal data: a peer-reviewed review of dialysis in Kuwait for 2013 to 2019 recorded 2,230 patients on dialysis in 2019, up 6% year on year, a prevalence of 465 per million population against an incidence of 100 per million, with 59% of the dialysis population diabetic and haemodialysis accounting for 89% of treatment. In oncology, the Kuwait Cancer Control Center in Shuwaikh is an accredited designated centre with a 200-bed complex, more than 600 oncology staff and over 2,000 new cancer patients a year drawn from Kuwait and the wider region, offering medical, surgical and radiation oncology alongside haemato-oncology and stem cell transplantation. Add a population of roughly 5.1 million of which about 70% are expatriates, with Indians the largest single group at over a million people, and the case for a reliable Indian supplier of parenterals is not a marketing argument but an arithmetic one. The bilateral relationship supports that case without overstating it. The Prime Minister of India's official visit to Kuwait on 21 and 22 December 2024, the first by an Indian prime minister in forty-three years, elevated the relationship to a Strategic Partnership. The joint statement records that a Joint Working Group on health already exists between the two countries and that Kuwait, then chairing the Gulf Cooperation Council, would support India-GCC cooperation under a joint action plan that includes health. No standalone pharmaceutical memorandum was signed at that visit, and we would rather say so than let a buyer plan around one. Farbe Firma Pvt Ltd works as both manufacturer and CDMO, which fits a market where the same molecule may serve a Ministry tender, a private hospital group and an insurance-funded clinic network at once. For Kuwait we supply CTD-structured dossiers with a Kuwait-specific regional module, Gulf-appropriate stability packages, bilingual Arabic and English artwork and inserts including Arabic-script brand presentation, and the legalised GMP certificates, manufacturing licences, Site Master File, Pharmacovigilance Master File, process validation protocols and per-batch certificates of analysis an exclusive Kuwaiti agent needs to open and then defend a file. Flexible batch sizes, own-label supply and technology transfer are available on the same quality system. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Who registers medicines and injectables in Kuwait? The Ministry of Health, through its Pharmaceutical and Herbal Medicines Registration and Control Administration, with Drug and Food Control as the operational contact function. The framework comes from Ministerial Decree No. 302/1980, the original guidelines for registration of pharmaceutical products, as updated and supplemented by Ministerial Decree No. 361 of 2019, which was published in January 2020 and sets out marketing authorisation holder registration, the local agent requirement, CTD dossier structure, bilingual labelling and a five-year registration validity. Does Kuwait require an exclusive local agent? Yes, for medicines registration, and this is the single most consequential structural fact about the market. The Ministry of Health requires an original legalised letter from the marketing authorisation holder appointing a sole and exclusive agent in the State of Kuwait, and regional counsel describe that requirement as admitting no exception, on the rationale that the Ministry needs one accountable party for record-keeping, pharmacovigilance and recalls. This sits in tension with Commercial Agencies Law No. 13 of 2016, which removed the exclusivity requirement for commercial agencies generally. The agency agreement should be registered with the Ministry of Commerce and Industry, because an unregistered agreement will not be heard by the Kuwaiti courts, and Kuwaiti law affords the agent protections including compensation on non-renewal where the relationship is exclusive or effectively so. What documents does a foreign manufacturer need for a Kuwaiti submission? At the site and holder stage: an original legalised letter appointing the exclusive Kuwaiti agent, an original legalised manufacturing licence from the health authority of the country of origin for each manufacturing site, an original legalised GMP certificate from that authority, a Site Master File and a Pharmacovigilance Master File. The Site Master File is expected to cover company history, capital and turnover for the past three years, site layouts, the quality control unit, personnel numbers and qualifications, premises and equipment, the product list and export countries, worldwide complaints, defects and recalls, and contract manufacturing arrangements. The Administration may require a GMP inspection visit to any named site. The product dossier then follows in CTD structure with a Kuwait-specific Module 1. Documents from India typically require legalisation through a chamber of commerce, the Ministry of External Affairs and the Embassy of Kuwait. How does drug pricing work in Kuwait and why does it matter to an exporter? Kuwait prices medicines against Gulf and international reference prices, reviewed periodically by specialised technical committees, and the Ministry states openly that the objective is for Kuwaiti prices to be among the lowest in the Gulf region. It acts on this frequently: 228 products priced in May 2024, price reductions on more than 200 medicines in July 2024, 146 new medicines priced in March 2025, decisions in August 2025 reducing prices on 400 medicines and approving 144 new ones, 392 approved and priced in October 2025, and in May 2026 reductions across around 1,922 medicines and supplements with 268 new products approved and priced. Prices are published in a public Ministry database and the October 2025 directives include enforcing adherence to set prices by companies and distributors. For an exporter the practical consequence is that the Kuwaiti price should be set with its effect on other Gulf reference baskets modelled in advance. What makes Farbe Firma a suitable injectable manufacturer for Kuwait? Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling on ISO Class 5 aseptic lines and exporting to more than 30 countries. For Kuwait we compile CTD-structured dossiers with a Kuwait-specific regional module, generate ICH Q1A(R2) and Q1B stability data defended on hot and humid conditions appropriate to Gulf storage and transit, work to IP, USP, BP and EP monographs, prepare bilingual Arabic and English artwork and package inserts including Arabic-script brand presentation, and maintain the Site Master File, Pharmacovigilance Master File, plant documentation and process validation records in an inspection-ready state because the Administration may inspect any named site. Certificates are issued in a form that survives chamber, ministry and embassy legalisation without a reissue. Contact info@farbefirma.com to discuss a specific molecule, tender or own-label programme. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 9, 2026 TL;DR: Eswatini is the market where our standing question stops working. We ask whether a country names the foreign regulators it leans on; Eswatini has not been operating a national registration system at all, so there is no decision for a foreign decision to be leaned into. The Ministry of Health's own 2021 policy says the country "is currently not actively registering medicines". What exists instead is a certificate test sitting on the import permit, and it is agency-agnostic: produce the product registration certificate from the regulator in the country of origin, whoever that regulator is. Key Takeaways There is no list, and no register either. We found no published Eswatini list of recognised foreign regulatory authorities and no instrument naming CDSCO, to recognise or to exclude it. The Ministry's 2012 import guideline requires product registration certificates for the medicines to be imported, "issued by the relevant authorities in the country of normal origin", plus batch analysis certificates. On its face an Indian certificate meets that description; we found no Eswatini statement confirming it in practice. The Act exists; commencement could not be confirmed. The Medicines and Related Substances Control Act (Act 9 of 2016; the short-title clause reads "2015") provides for a Medicines Regulatory Authority, but section 1(2) brings it into force on a date appointed by the Minister in the Gazette — we found no commencement notice and could not access a searchable Gazette. The Authority's board was reported unveiled on 8 January 2026, with no register, no finalised regulations and no quality-control laboratory behind it. The binding constraint is the importer, decisively. Imports must run through the Ministry or through authorised pharmaceutical importers registered with it; the criteria are suitable warehousing premises and suitably qualified pharmaceutical personnel, and the certificate names a supervising pharmacist. Permit validity shall not exceed six months, and no importation of medicines may be done by post. The gate that actually bites is a donor rule, not an Eswatini rule. About 28% of current health expenditure was external money in 2023, and the Global Fund's Quality Assurance Policy requires WHO prequalification, an SRA, a WLA or ERP review for antiretroviral, anti-tuberculosis and antimalarial products — its ERP route requiring GMP verified by WHO-PQ, an SRA or WLA, or a PIC/S authority, which is where India's PIC/S non-membership tells. Introduction: Why Eswatini Demands a Premium Injectable Manufacturer in Eswatini Every market in this series opens by asking whether the country publishes a list of foreign regulatory authorities it will lean on, and whether India's CDSCO is among them. Eswatini is the first where the honest answer is that the question does not fit. The Ministry of Health's National Pharmacovigilance Policy of June 2021 states that the country "is currently not actively registering medicines", and that suppliers are registered as importers and issued an import certificate while "these products are not considered as being registered". There is no registration decision into which a foreign decision could be leaned. What operates in its place is a documentary test at the border, and it is agency-agnostic. The 2012 import guideline asks for the product registration certificate issued by "the relevant authorities in the country of normal origin" — open-ended, with no list of acceptable authorities anywhere in it. The Ministry's own medicines database asks which authority registered a product without restricting which authorities count. So an Indian certificate is, on the published documents, the same kind of object as anyone else's. We found no statement confirming that in practice, and a serious injectable manufacturer in Eswatini does not upgrade a silence into a permission. What Sets a World-Class Injectable Manufacturer in Eswatini Apart Site rules and product rules must be kept apart: on the statute book both exist, and in practice neither operates as written. Part VI of the 2016 Act provides for manufacturer, wholesaler and import or export licences, issued on conditions relating to good manufacturing and distribution practices, valid for not more than three years. But the licensing subjects are defined by reference to premises licensed under the Pharmacy Act, 1929 — and the text of that Act we read registers chemists as persons and contains no premises-licensing provision we could identify. We found nothing creating a foreign-site licence or an overseas GMP inspection programme. So a WHO-GMP certificate is commercially and donor-relevant here rather than legally operative. We found no Eswatini legal instrument that requires it, evaluates it, or confers status on it; it is in neither the 2012 guideline's document list nor the published tender advert — though the Instructions to Tenderers is not downloadable and we could not obtain it, so that is "not stated in the advert", never "not required". Nor is there a national quality-control laboratory: reporting in 2026 describes incoming stock checked by visual inspection. Quality Systems Behind Every Injectable Supplied to Eswatini With no national dossier standard published, the discipline has to come from the manufacturer's own systems and the channels that do impose one. We found no published Eswatini dossier-format requirement — section 24(2) of the Act defers the content of an application entirely to the Authority or to regulations, and we found no evidence regulations have been finalised — so CTD and ACTD are what a serious supplier brings, not what Eswatini demands. That means aseptic process simulation for the ISO Class 5 filling line, environmental monitoring, container-closure integrity, sterility and LAL endotoxin testing, and validated HPLC and GC methods, with ICH Q1A and Q1B stability behind them. On stability, report the position rather than a number. We found no Eswatini-published stability guideline. A SADC annexure reproduced in Zambia's stability guideline, derived from a WHO table updated 1 February 2013, assigns Swaziland long-term conditions of 25 °C and 60% relative humidity — Climatic Zone II. Do not read that as a relaxation: a supplier covering neighbouring SADC markets would in practice generate 30 °C and 75% data, and be right to. Eswatini is a non-active ZaZiBoNa member, does not appear on WHO's ML3 or ML4 list, is not a PIC/S participating authority, and has not signed the African Medicines Agency Treaty. Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry. Why Farbe Firma is the Trusted Injectable Manufacturer in Eswatini for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. We hold no Eswatini registration, licence or accreditation and claim none. What we supply is what the published route asks for: the Indian product registration certificate, the batch certificate of analysis, full manufacturer particulars, and the product data the import permit needs. The rest sits with a locally authorised importer holding Ministry registration, compliant warehousing and a named supervising pharmacist. Public tendering is a separate track, and the common assumption about it is wrong. Section 39 of the Public Procurement Act 2011 prohibits excluding a tenderer on grounds of nationality, and the national Standard Tender Document states that all countries are eligible and that the provider's nationality does not determine the goods' origin. A Swati agent is a price-preference lever, not an access gate: an unrepresented foreign bidder can be evaluated at up to 15% above its actual price, and partnering caps that at 7.5%. The barriers are physical, not legal — sealed paper bids to the Treasury Tender Box in Mbabane — and bidders must enclose a Manufacturer's Authorisation. Three market facts, each with its basis. Roughly 28 cents in every health dollar was donor money in 2023, so a large slice of the medicines market is donor-procured rather than government-tendered — and for antiretroviral, TB and antimalarial products the Global Fund gate applies, which CDSCO's vaccines-only ML3 scope and India's PIC/S non-membership do not open. Population carries its basis: the 2017 census enumerated 1,093,238 and the World Bank estimate for 2025 is 1,256,174, so every per-capita figure rests on projection. And the bilateral ground is better than the paperwork suggests — about 2,000 Indians live in Eswatini, around 90% of them from Gujarat. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Does Eswatini accept Indian CDSCO product registration? We found no Eswatini instrument that names CDSCO, to recognise or to exclude it. The published import guideline requires the product registration certificate issued by the authority in the country of origin, without naming which regulators qualify; on its face an Indian certificate meets that description. We found no statement confirming this in practice, and a Ministry communications officer has been quoted saying suppliers must source from accredited manufacturers, with orders from manufacturers not on the list rejected. We found no published list, criteria or statutory basis for that, and it rests on a single secondary source. Who is Eswatini's medicines regulator today? Regulatory functions have in practice been carried out by the Medicines Regulatory Unit within the Ministry of Health. The Act establishes a Medicines Regulatory Authority, whose board was reported unveiled on 8 January 2026 by two Eswatini outlets; we found no primary or official-government confirmation, and no evidence the Authority has begun registering medicines. Eswatini media use both "MRA" and "EMRA"; no primary source we found uses "EMRA". Do not confuse this with EMSA, the Eswatini Medical Supplies Agency, a supply-chain body and not a regulator. Is a CPP or a GMP certificate required to supply Eswatini? We found no published Eswatini requirement for either. The 2012 guideline's introduction stresses the WHO Certification Scheme, but the Certificate of a Pharmaceutical Product does not appear in its actual documentation requirements — what it requires is the country-of-origin registration certificate and batch analysis certificates. A GMP certificate is likewise absent from the document list and the published tender advert. Both statements are about what the published documents say; the Instructions to Tenderers could not be obtained, and regulations under section 72 could impose either. Does a ZaZiBoNa approval let you sell in Eswatini? No. ZaZiBoNa is a collaborative registration initiative that issues recommendations from joint assessment; its own site states those can be used to support registrations at country level. Registration remains a national act, and Eswatini is not currently registering medicines, so there is nothing for a recommendation to convert into. Eswatini is a non-active member — active status requires assessment and GMP inspection capacity. It may become relevant later; it is not a route into Eswatini today. What can Farbe Firma actually do for a partner supplying Eswatini? Manufacture, and supply the documents the route asks for. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. We prepare CTD and ACTD dossiers, provide the Indian registration certificate, batch certificates of analysis, WHO-format CPP and GMP certificate, and ICH Q1A and Q1B stability data. We work through a locally authorised importer, and we make no claim to be registered, listed or accredited in Eswatini. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 5, 2026 TL;DR: Bahrain answers the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — with a clear yes and a clear no. The National Health Regulatory Authority's Medicine Licensing Guideline of 20 October 2025 names six fast-track reference authorities (the Gulf Health Council's central registration, SFDA, US FDA, EMA, Swissmedic and MHRA), a second list on its application form, a third list of GMP 'competent authorities' for licensing foreign sites and a nineteen-country pricing basket, and India's CDSCO is on none of them. Absence is not exclusion: the normal 45-working-day pathway is open to any origin that can furnish a legalised WHO-format CPP, a home-regulator GMP certificate, one year of home-market sales, an eCTD dossier and samples for NHRA laboratory testing. The hard knot is site licensing, which as written wants GHC site registration or a Western or Japanese GMP certificate — for a sterile product, for both bulk manufacturer and batch releaser. The commercial gate is consolidating under the Supreme Council of Health's unified-procurement committee, with the Health Insurance Fund as the government's importer. Key Takeaways A named list, and India is not on it. Fast-track registration in ten working days requires prior approval by the GHC central committee, SFDA, US FDA, EMA, Swissmedic or MHRA; the application form separately asks whether the product is licensed by the GHC, US FDA, Health Canada, TGA, EMA or nine European agencies. There is no WHO-prequalification or generic stringent-authority clause to argue under, and the WHO's August 2026 maturity list places CDSCO at level 3 for vaccines only. The normal pathway is a certificate test. Forty-five working days; a legalised WHO-format CPP from the batch-releaser's country; a country-of-origin GMP certificate; at least one year on the home market; an eCTD dossier to GHC and ICH structure; NHRA laboratory analysis before first import — 50 ampoules, 25 vials or 20 prefilled syringes; a five-year licence cancelled if the product is not marketed within two. A licensed Bahraini pharmacy acts as local agent; the distributor cannot be the marketing-authorisation holder. Site licensing is the knot. Before any product application the foreign site needs an NHRA licence, and checklist item 12 asks for a GHC site-registration certificate or, failing that, a GMP certificate from one of eleven authorities — EudraGMP, Ireland, Germany, France, MHRA, US FDA, Health Canada, TGA, Medsafe, Swissmedic or Japan — beside the home-country GMP certificate; sterile products need licences for both bulk manufacturer and batch releaser. Whether NHRA accepts alternatives in practice we could not verify, so the practical Indian route begins with GHC site registration. Price is set by a basket India is not in. The generic CIF price is the lowest of origin ex-factory plus freight, the lowest CIF in Kuwait, Oman, Qatar, Saudi Arabia, the UAE, Egypt, Jordan, Turkey and eleven Western markets, the price of similar registered drugs, or a ladder that cuts each successive generic; CIF is fixed in US dollars at 0.377 dinars. Buyers are consolidating under the Supreme Council of Health's unified-procurement committee, and adult diabetes prevalence was 22.1% in 2024. Introduction: Why Bahrain Demands a Premium Injectable Manufacturer in Bahrain Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? Bahrain, the first Gulf market in the series, answers with unusual precision, because the National Health Regulatory Authority writes its lists down. The operative text is the NHRA Medicine Licensing Guideline, version 4.1 of 20 October 2025, which we read in full. Its fast-track pathway — ten working days against forty-five for the normal route — is open only to products already approved by the Gulf Health Council's central registration, Saudi Arabia's SFDA, the US FDA, the EMA, Swissmedic or the UK's MHRA, with the batch-release site registered with one of them. The application form asks separately whether the product is licensed by the GHC, the US FDA, Health Canada, the TGA, the EMA or the agencies of nine European countries, and the bioequivalence-centre rule accepts GHC-approved sites or those approved by the WHO, US FDA, Health Canada, TGA, MHRA or EMA. India appears in none of these lists, and there is no WHO-prequalification clause, no maturity-level clause and no generic stringent-authority clause anywhere in the guideline under which an Indian approval might be argued in. So the answer to the standing question is a plain no, and the more useful question is what the no costs. It does not cost market access. The normal pathway does not discriminate by country of origin; what it demands is paper and product: a WHO-format certificate of a pharmaceutical product, legalised and issued in the batch-releaser's country, a GMP certificate from that country's health authority, proof that the medicine has been marketed at home for at least one year, an eCTD dossier to the GHC and ICH common technical document, and samples for mandatory laboratory analysis before the first importation — 50 ampoules, 25 vials, 20 prefilled syringes or 5 units of a small-volume solution, with reference standards and full methods — quantities the guideline itself calls approximate and subject to change. A licence runs five years and is cancelled if the product is not marketed within two. The fee schedule sits in a 2016 resolution we could not fetch, so the only figure we print is the 50-dinar hospital-pack fee. A premium injectable manufacturer in Bahrain, then, treats the certificate test as a discipline rather than a formality — and solves the site-licensing problem before filing a single product. What Sets a World-Class Injectable Manufacturer in Bahrain Apart The site-licensing problem is the real gate. NHRA's International Manufacturing Site Licensing Procedure, version 1.6 of the same October 2025 date, makes licensing of the foreign manufacturing site mandatory before any product application. Item 12 of its checklist asks for a valid Gulf Health Council site-registration certificate or, if the applicant cannot supply one, a GMP certificate from a named competent authority — EudraGMP, Ireland's HPRA, Germany, France's ANSM, the MHRA, the US FDA, Health Canada, the TGA, New Zealand's Medsafe, Swissmedic or Japan's health ministry — and item 13 separately requires the GMP certificate of the country of origin. For sterile formulations both the bulk manufacturer and the batch releaser must hold NHRA site licences. The licence is assessed in thirty working days, runs five years and lapses if no product is registered within three. As written, an Indian site with only Indian GMP certification cannot satisfy item 12; whether NHRA exercises discretion in practice we could not verify and do not assert. The honest consequence is that the Indian route to Bahrain begins in Riyadh rather than Manama: with the GHC's central registration committee, created by the Gulf health ministers in 1998, which inspects factories and registers companies under unified regulations, and whose registration Bahrain accepts as a fast-track reference, as a substitute for the CPP and as a substitute for the competent-authority GMP certificate. Two further layers deserve care. First, the GHC's own reference-authority text was not obtained; the only description we found is a 2022 academic evaluation, based on GHC data, reporting that a product approved by two Gulf states or by the US FDA, the EMA or WHO prequalification receives an abridged review, that reliance began at the end of 2019, and that generics are within scope. We report that as the literature's account, not the GHC's rule. Second, the pricing regime. Annex IV of the licensing guideline and the Medicine Pricing Guideline of January 2022 require prices in Kuwait, Oman, Qatar, Saudi Arabia and the UAE and in Australia, Belgium, Canada, Denmark, Egypt, France, Germany, Ireland, Jordan, Spain, Sweden, Switzerland, Turkey and the UK, plus the country-of-origin prices. A generic's CIF price is the lowest of four figures: origin ex-factory plus freight, the lowest CIF anywhere in the basket, the price of similar registered products, or a ladder under which the innovator drops 20% on first generic entry and each successive generic is priced 15%, then 10%, below the one before. CIF is fixed in US dollars at 0.377 dinars, retail is 1.35 times CIF up to 20 dinars and 1.25 above, and prices are revisited at renewal and whenever the home-market price falls. An Indian ex-factory price therefore sets a ceiling, never a floor. Quality Systems Behind Every Injectable Supplied to Bahrain For a sterile injectable the evidence an assessor or inspector expects is the same in Manama as anywhere: aseptic process simulation records for the ISO Class 5 filling line, environmental monitoring trends, container-closure integrity, sterility and bacterial endotoxin testing by LAL, particulate matter, validated HPLC and GC assay and impurity methods, and ICH Q1A and Q1B stability data for a hot, humid Gulf climate under the GCC stability guideline NHRA cites. Because analysis by an NHRA-authorised laboratory is mandatory before the first import and a second failure means rejection, the certificate of analysis, reference standards and methods that accompany the samples must be written to be reproduced by a laboratory that has never seen the product. The international layers are quickly stated. Bahrain's NHRA does not appear on the WHO's August 2026 list of authorities at maturity level 3 or 4; the only Gulf authority on it is Saudi Arabia's SFDA, at level 4. India's CDSCO appears on that list for vaccines only, so even a generic maturity-level clause would not carry a small-molecule injectable from India, and Bahrain has no such clause in any case. Neither Bahrain nor India is a PIC/S participating authority. The Indian Pharmacopoeia Commission's recognition list of 10 July 2026 names twenty-four countries and no Gulf state, and the NHRA form asks for the pharmacopoeial standard of each ingredient, so the file should cite the USP, BP or Ph. Eur. monograph where one exists. The founding law, No. 38 of 2009, has not been superseded; Decree-Law 12 of 2023 amended it to move narcotic and psychotropic licensing to NHRA. The leaflet must be supplied in Arabic and English and the SmPC in English. Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry. Why Farbe Firma is the Trusted Injectable Manufacturer in Bahrain for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries, among them Gulf and Middle Eastern markets where the GHC eCTD structure and GCC stability conditions are the working standard. We build dossiers in CTD and ACTD format, which is the structure NHRA requires in eCTD, and we supply the WHO-format certificate of a pharmaceutical product, the manufacturing licence and the GMP certificate as a matter of course. Because the guideline requires import and distribution through a licensed Bahraini pharmacy acting as local agent under a legalised contract, our route is a named pharmacy-agent in Bahrain, GHC site registration for the sterile line as the first regulatory act, and a price file built from the basket rather than from our list price. The bilateral relationship is large and the pharmaceutical line in it is new. The Ministry of External Affairs brief of June 2024 records bilateral trade of USD 1,738.86 million in 2023–24, with Indian exports of USD 909.42 million, and names 'medicaments' among India's exports as a recent addition, beside rice, meat, sugar, machinery, jewellery and polymers. There is a health instrument: a memorandum on cooperation in healthcare signed in July 2018, under which an India–Bahrain Joint Working Group on Healthcare first met on 22 February 2022; NHRA's chief executive attended Pharmexcil's iPHEX and regulators' conclave in New Delhi in September 2022. We found no agreement between NHRA and CDSCO. Reports of the fifth High Joint Commission in New Delhi on 3 November 2025 say the two sides agreed to begin negotiating a comprehensive economic partnership agreement; no such agreement exists yet. UN Comtrade's public preview returns Indian pharmaceutical exports to Bahrain of about USD 8.7 million in 2024 and USD 9.4 million in 2025, but flags every record as an estimate, so we quote the order of magnitude and nothing finer. The Indian community, which the two MEA briefs put at 340,000 and 350,000, is roughly a quarter of the population. Where the money is: Bahrain has 1.60 million people, gross national income per capita of USD 28,790 in 2025, current health expenditure of about USD 1,176 per person and 4.0% of GDP in 2023, and life expectancy of 81.4 years. Out-of-pocket payments were 28.7% of health expenditure in 2023 and rising, and diabetes prevalence among adults was 22.1% in 2024, up from 19.5% in 2011; the UNDP investment case for Bahrain is reported to attribute three quarters of deaths to the four main non-communicable diseases. Public purchasing is being consolidated under the Supreme Council of Health, whose National Committee for Unified Procurement of Medicines and Medical Supplies approves purchase contracts, holds the strategic national stock and prepares the essential-medicines list, and whose membership names the buyers: the Health Insurance Fund as vice-chair and, per the health minister's 2024 statement, the government's importer of record; King Hamad University Hospital; the Bahrain Defence Force Hospital; the Bahrain Oncology Center; the specialist cardiac centre; the government hospitals; and primary care. Ministry of Health tenders are advertised through the Tender Board portal, and the committee's brief includes increasing Bahrain's share of the GCC Joint Procurement Programme, whose 2026 tender schedule is published and whose supplier prerequisites we could not obtain. Hospital pack sizes supplied to tenders must be registered with NHRA, and injectable hospital packs of one to ten units are not accepted unless they are at least five times the largest registered pack. The national health insurance law of 2018 is the frame for all of it; the pace of its rollout in 2026 we report only as claimed. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Is India on Bahrain's list of recognised regulatory authorities? No. NHRA's Medicine Licensing Guideline of 20 October 2025 names the GHC central registration, SFDA, US FDA, EMA, Swissmedic and MHRA as fast-track reference authorities, lists the GHC, US FDA, Health Canada, TGA, EMA and nine European agencies on its application form, and lists eleven Western and Japanese authorities as GMP 'competent authorities' for site licensing; CDSCO is on none, and there is no WHO-prequalification or maturity-level clause. Absence is not exclusion: the normal 45-working-day pathway accepts a legalised WHO-format CPP and GMP certificate from India once the site is licensed by NHRA. What law governs medicine registration in Bahrain? Decree-Law 18 of 1997 on the practice of pharmacy, amended by Decree-Law 20 of 2015, with Resolution 63 of 2019 and the Supreme Council of Health's registration and pricing regulation, Resolution 32 of 2020 as amended by Resolution 46 of 2023; NHRA itself was created by Law 38 of 2009, amended by Decree-Law 12 of 2023. The operative rules are NHRA's Medicine Licensing Guideline version 4.1 and Site Licensing Procedure version 1.6, both of 20 October 2025, and the Pricing Guideline of January 2022. Dossiers are eCTD; licences run five years; fees follow Decree 17 of 2016, whose schedule we could not fetch. Can an Indian manufacturer get its site licensed by NHRA? As written, only with a Gulf Health Council site-registration certificate or a GMP certificate from one of eleven listed authorities — EudraGMP, Ireland, Germany, France, the MHRA, US FDA, Health Canada, TGA, Medsafe, Swissmedic or Japan — in addition to the Indian GMP certificate. Whether NHRA accepts alternatives in practice we could not verify. For a sterile product both the bulk manufacturer and the batch releaser need licences. The practical sequence is GHC site registration first, then the NHRA site licence, then the product. Who buys injectables in Bahrain? Government purchasing is consolidating under the Supreme Council of Health's National Committee for Unified Procurement, with the Health Insurance Fund as the government's importer and King Hamad University Hospital, the Bahrain Defence Force Hospital, the Bahrain Oncology Center, the cardiac centre, the government hospitals and primary care at the table; Ministry of Health tenders are advertised through the Tender Board portal, and Bahrain takes part in the GCC Joint Procurement Programme. Every product reaches the market through a licensed Bahraini pharmacy as local agent, and hospital pack sizes must be registered with NHRA before they can be tendered. Does Farbe Firma have experience with GCC markets? Yes. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries, including Gulf and Middle Eastern markets. We prepare dossiers in CTD and ACTD format to the GHC and ICH eCTD structure, generate stability data under GCC conditions, supply the WHO-format CPP, manufacturing licence and GMP certificate, and work through licensed local agents with Arabic and English leaflets. Write to info@farbefirma.com with the product list and we will map it to the NHRA pathway and the pricing basket. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 6, 2026 TL;DR: Timor-Leste answers the question we ask of every market — does it name the regulators it will lean on, and is India's CDSCO among them — with a named list on which CDSCO does not appear. The list is a route switch, not a bar: question E1 of the DNFM's registration form names ten agencies plus WHO prequalification, yes sends the file to Route A and no sends it to Route B, and both branches end in a registration number. Two harder facts frame it: the statutory basis is in transition, and the applicant must be an importer seated in the country. Key Takeaways A named list, and CDSCO is not on it — but WHO prequalification is. Question E1 of the DNFM importer application form of January 2024 names Indonesia's BPOM, Singapore's HSA, Thailand's FDA, Malaysia's NPRA, the TGA, the EMA, Health Canada, Swissmedic, Japan's PMDA and the US FDA, plus WHO prequalification. CDSCO is absent there, and from the 2018 form and 2023 checklist. WHO's August 2026 list records CDSCO at maturity level 3 with the scope 'Vaccines (producing)' only. Route B is a documentation route, not a refusal: a GMP certificate for the finished-product site issued no longer than two years ago, a valid CPP for export to Timor-Leste — free-sale certificates are not accepted in its place — a batch certificate of analysis, the list of countries where the product is approved, three-batch stability with the climate zone declared, a full ASEAN Common Technical Dossier on USB, and a sample. The DAIM procedure sets a 30-day target and 90-day maximum. The legal basis is in transition and should be said plainly. Decree-Law 12/2004 was repealed in full by Article 77 of Decree-Law 2/2025, in force from 23 January 2025, although the DNFM's forms still cite it. Article 56(2) cross-refers to a marketing-authorisation decree-law that we searched for in the Jornal da República for 2025 and 2026 and did not find published. You cannot be the applicant, and the money is at INFPM. Article 44(a) of Decree-Law 2/2025 requires the authorisation-holder to be seated in national territory and Article 44(d) requires a pharmacist as technical director. SAMES was succeeded by the Instituto Nacional de Farmácia e Produtos Médicos under Decree-Law 57/2023, which publishes tenders and awards; our own approximate count of its published medicine awards is twelve lines worth about USD 2.01 million. Introduction: Why Timor-Leste Demands a Premium Injectable Manufacturer in Timor-Leste Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? Timor-Leste answers it in one line on a form. Question E1 of the DNFM importer medicine application form, version 2.1 of January 2024, asks whether the product is approved by one of ten named agencies — among them Indonesia's BPOM, Singapore's HSA, the TGA, the EMA and the US FDA — or is WHO-prequalified. Yes sends the file to Route A; no sends it to Route B. CDSCO is not among them, and it is absent from the 2018 form and the September 2023 checklist too. That absence is not exclusion. Nothing we read says a product from an unlisted country is refused, and the registration numbering scheme — AIMTL, year, route letter, sequence — shows Route B files end in registrations. A published DNFM FAQ states the intent plainly: future requirements will streamline registration for medicines authorised by trusted regulatory bodies, while additional data is needed for others. So the answer costs paperwork rather than access, and a serious injectable manufacturer in Timor-Leste plans for it. One caution: the 2018 form, the 2023 checklist and the 2024 forms remain published simultaneously with overlapping but not identical country sets, and we could not establish which is currently operative. What Sets a World-Class Injectable Manufacturer in Timor-Leste Apart The rules about your factory and the rules about your buyer's licence are different rules, and here the binding one sits on the buyer. On the factory side the requirements are demanding but not origin-restricted: the GMP certificate must be current within two years and no instrument we read says which authority must issue it, and the 2018 form warns that a manufacturing licence is not the same thing as a GMP certificate. On the local side, Article 44(a) of Decree-Law 2/2025 requires the authorisation-holder to be seated in national territory, Article 44(d) requires a permanent and exclusive pharmacist as technical director, and Article 51 requires climate-controlled distribution. The transition in the statute is the fact most easily glossed. Decree-Law 12/2004 was repealed in full by Article 77 of Decree-Law 2/2025 of 22 January 2025, and the DNFM's published forms still cite it as their legal basis. Article 56(2) of the new decree-law cross-refers to a separate decree-law on marketing authorisation; we searched the Jornal da República Série I for 2025 and 2026 and did not find it published. Diploma Ministerial 10/2004 sets the registration fee at USD 100 per medicine per form and dosage, though whether that schedule survives the repeal of its parent decree-law is unconfirmed. We searched in English, Portuguese and Tetum and found no body called ANMAS. Quality Systems Behind Every Injectable Supplied to Timor-Leste For a sterile injectable the technical file is where a Route B application is won, because no national laboratory stands behind it — the April 2025 policy records that there is currently no laboratory testing of medical products through national laboratories, while a physical sample still travels with the file. Expect aseptic process simulation records for the ISO Class 5 filling line, environmental monitoring trends, container-closure integrity, sterility and bacterial endotoxin testing by LAL, particulate matter, and validated HPLC and GC methods for assay and impurities. On stability the instruments differ and both readings should be reported: the September 2023 checklist specifies three batches in Zone IVb, 30°C and 75% relative humidity, while the 2024 forms let the applicant declare Zone IVa, Zone IVb or other, and a published FAQ warns that a shorter shelf life may be applied where Zone IVb data cannot be provided. Shelf lives under 24 months are generally not acceptable, with exceptions. The bioequivalence rationale is scoped to oral solids and does not bite on injections. Neither Timor-Leste nor India appears on the PIC/S list of 54 participating authorities. Labelling must be in Tetum and Portuguese, or provisionally Indonesian or English. Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry. Why Farbe Firma is the Trusted Injectable Manufacturer in Timor-Leste for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries, positioning itself to serve Timor-Leste through a locally licensed importer. We build dossiers in CTD and ACTD format, which is the structure Route B asks for, and supply the WHO-format certificate of a pharmaceutical product, the manufacturing licence and the GMP certificate as a matter of course. Because the applicant must be based in Timor-Leste with an import licence and a pharmacist to sign, the route begins with a named local partner. Candidates are visible in the public record, but we have verified none and recommend none. The bilateral relationship is young and its pharmaceutical content is thin but real. India announced a resident mission in Dili on 7 September 2023 and established the embassy on 5 September 2024. The two countries signed a memorandum on cooperation in healthcare on 7 April 2018, which expired in April 2023 and has been renewed for five years; it is a cooperation instrument, and we found nothing in it touching medicine registration, pharmacopoeial recognition or regulatory reliance. The Embassy of India in Dili reports total bilateral trade of USD 52.20 million in 2025–26; we could not locate a disaggregated pharmaceutical figure. Where the money is, with every figure carrying its basis. Population is roughly 1.4 million: the World Bank estimate is 1,400,638 for 2024, while the 2022 census recorded 1,341,737 usual residents. Current health expenditure was 9.60% of GDP in 2023, up from 7.46% in 2022, but spending per person fell from USD 174.92 to USD 144.21 because GDP contracted — the share rose and the spending did not. Out-of-pocket payments were 6.99% of current health expenditure in 2023. Our own approximate count of INFPM's published medicine awards on 6 September 2026 is twelve lines totalling about USD 2.01 million, and a specialist-medicines tender with a USD 530,000 budget was open, closing 14 September 2026. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Is India on Timor-Leste's list of recognised regulatory authorities? No. Question E1 of the DNFM importer application form of January 2024 names ten agencies plus WHO prequalification, and India's CDSCO is absent, as it is from the 2018 form and the 2023 checklist. Absence is not exclusion: E1 selects Route A or Route B, and both end in a registration number. WHO's August 2026 list records CDSCO at maturity level 3 for vaccines only. What law governs medicine registration in Timor-Leste? The position is in transition. Decree-Law 12/2004 was repealed in full by Article 77 of Decree-Law 2/2025 of 22 January 2025, although the DNFM's published forms still cite it. Decree-Law 2/2025 regulates the licensing of import, storage, distribution, sale and export, and its Article 56(2) cross-refers to a separate decree-law on marketing authorisation that we searched for and did not find published. In practice the operative documents are the DNFM's form, checklist and DAIM procedure. Does an Indian manufacturer need WHO prequalification to supply Timor-Leste? No, but it changes the route. WHO prequalification is named on the form as a Route A qualifier, so a WHO-prequalified product takes the abridged route. Without it an Indian product goes to Route B. WHO prequalification is product- and site-specific; WHO-GMP certification by an Indian state licensing authority is a different thing, is not named on the form, and we found no instrument treating the two as equivalent. Who buys injectables in Timor-Leste? Mainly the state. SAMES was succeeded by the Instituto Nacional de Farmácia e Produtos Médicos under Decree-Law 57/2023, which procures, stores and distributes from a central warehouse in Dili and regional units at Ainaro, Baucau and Maliana. It publishes tenders and results with budgets, winning bidders and amounts; our own approximate count of its published medicine awards is twelve lines worth about USD 2.01 million. Suppliers must hold a valid import or wholesale licence to bid. Does Farbe Firma have experience with ASEAN and Asia-Pacific markets? Yes. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries, including Asia-Pacific markets where the ASEAN Common Technical Dossier is the working format. We prepare dossiers in CTD and ACTD structure, generate Zone IV stability data, supply the WHO-format CPP and GMP certificate, and work through licensed local importers. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: August 28, 2026 TL;DR: Georgia is famous for a seven-working-day medicines registration, and for an Indian manufacturer that headline is the wrong one to read. The Law on Medicines and Pharmaceutical Activities creates two separate routes: a recognition regime, which unilaterally accepts approvals from a fixed list of foreign regulators and skips the scientific assessment entirely, and a national regime, which is a full technical review. The recognised list is set by Government Resolution No. 188 of 22 October 2009 and its three amendments, and India is not on it – neither is WHO Prequalification. So the fast lane is shut and the national lane is the one that matters. The good news is that the national lane is unusually workable: WHO-GMP is an expressly recognised standard in Georgia, the statutory fee for a generic is GEL 500, the decision clock is three months, the Agency may raise deficiencies only twice, and if it says nothing in time the product is deemed registered. The real costs are Georgian-language filing, three paper copies and physical samples with reference standards – not the fee. Key Takeaways Georgia's fast-track is closed to Indian files, and the article that says otherwise is quoting a list it has not read. Article 11-4 of the Law on Medicines and Pharmaceutical Activities splits registration into a recognition regime and a national regime. The recognition regime is a homology check only – no repeat expertise, entry in the registry within seven working days – but it is available only for products already authorised by a regulator on the list fixed by Government Resolution No. 188 of 22 October 2009. That list was amended three times, adding Israel in 2013, Croatia in 2021 and Turkiye in 2022, and it contains the EMA, the United States, Japan, Canada, Australia, Korea, Switzerland, Norway and the EU and EEA member states. It does not contain India, CDSCO or WHO Prequalification. A liberal regime is not automatically an open one. The national regime is the real route, and it is genuinely benign. Article 11-11 gives a fourteen-day administrative completeness check, a three-month decision period for a first registration, twenty calendar days for a Type IA variation and forty for a Type IB, and a two-month cure period for deficiencies which the Agency may raise only twice. Most strikingly, Article 11-11(10) provides that if the applicant is not notified of a refusal within the statutory period the product is considered registered and the authorisation document must be issued. Circulation is permitted for five years, and re-registration must be filed no later than two months before expiry or the product falls back to a primary application. WHO-GMP is expressly enough – this is the single most important fact for an Indian site. Government Resolution No. 349 of 16 November 2010 lists the GMP standards Georgia recognises, and WHO-GMP heads that list alongside EC GMP, US FDA cGMP and PIC/S GMP. Its Article 1-prime obliges the registering body to accept a manufacturing-compliance document issued by a competent authority under any of those standards. Georgia's own national GMP standard is EC GMP, but that obligation runs to holders of Georgian manufacturing permits – domestic plants – not to importers. You do not need an EU-GMP certificate to file a WHO-GMP injectable in Georgia. The fee is trivial and the price is capped by statute – model the ceiling, not the volume. Under the Law on Registration Fees a generic registration in the national regime costs GEL 500, a re-registration GEL 200, and a Type II documentation variation GEL 50, against GEL 2,500 for a new original product. At the other end, the Law on Medicines defines reference wholesale and retail prices as statutory maxima, obliges the Ministry to publish a reference price catalogue, and prohibits selling above it – with import, export and re-export transactions expressly carved out. In a market where the World Bank puts out-of-pocket spending at 58.76% of current health expenditure, a legislated ceiling structurally favours the cheapest compliant supplier. Introduction: Why Georgia Demands a Premium Injectable Manufacturer in Georgia Georgia is a small, wealthy-for-its-region market that punishes assumptions. The World Bank puts the population at 3,935,766 and gross national income per capita at US$8,990 for 2025, with current health expenditure at 6.86% of GDP and US$554.32 per person in 2023 – figures that sit well above most of the markets an Indian injectable exporter works in. But 58.76% of that health spending came out of patients' own pockets in 2023, which is the number that actually governs commercial behaviour. Price is not a secondary consideration in a majority out-of-pocket market; it is the first one. The therapeutic demand is real and injectable-heavy: GLOBOCAN 2024 records 16,063 new cancer cases and 7,780 cancer deaths a year in Georgia with 45,921 people alive within five years of a diagnosis, WHO estimates 1,700 tuberculosis cases in 2024, and the European Union Agency for Asylum's December 2025 medical country report – citing Georgia's National Center for Disease Control – records renal failure prevalence of 102.2 per 100,000 with haemodialysis available in 50 of the country's 64 municipalities as of July 2025 under a state dialysis and kidney transplant programme that covers the cost of treatment. What makes Georgia genuinely distinctive is its regulatory architecture, and it is almost universally described incorrectly in supplier marketing. Georgia unilaterally recognises the decisions of a fixed list of foreign regulators and, for products they have approved, carries out no repeat scientific assessment at all – an unusually generous piece of regulatory policy for a country of four million people. That has produced a stream of content promising seven-working-day registration in Georgia. For a manufacturer whose product is registered in India and made to WHO-GMP, that promise does not apply, because India is not one of the recognised regulators. The useful article is the one that says so in the first paragraph and then explains, accurately, what the route that is open actually requires. That is what follows. What Sets a World-Class Injectable Manufacturer in Georgia Apart The national regime has an unusual shape and it rewards preparation in places an Indian regulatory affairs team will not expect. Article 11-11 of the Law on Medicines requires that the applicant be the manufacturer of the product or a trade licence holder – unlike the recognition route, which any interested person may use. It then splits the dossier in two: the administrative part must be filed in tangible form in the Georgian language, while the scientific and technical part may be filed in Georgian, Russian or English, in three identical paper copies, with an electronic copy alongside. The administrative part wants an original certificate of a pharmaceutical product in the form recommended by the World Health Organization or, where one is not available, a document certifying manufacture to the GMP standard or a manufacturing licence issued by the authority of the manufacturing country, plus an attested Georgian translation of the patient information leaflet and a standard pack. For a generic, the scientific part wants composition per dose unit, active substance monographs with the name and address of every API manufacturer, excipient monographs, finished-product specifications and methods, a manufacturing process flow chart, stability data and equivalence data determined according to WHO recommendations having regard to the dosage form and route of administration. Two of those requirements are logistics problems rather than paperwork problems, and they are what separate a supplier who can actually execute in Georgia from one who cannot. The first is physical: two standard packs plus enough material for two tests with certificates of analysis, and a reference standard sufficient for two tests, also with a certificate. For a lyophilised or cold-chain injectable that is a genuine shipping, customs and stability exercise, not an envelope. The second is translation: an attested Georgian leaflet and a Georgian-language administrative file, produced to a standard that survives an Agency reading, at the same time as a Russian or English technical file. Neither is expensive relative to the GEL 500 statutory fee for a generic, but both take calendar time, and calendar time is the scarce resource when the Agency's own clock is only three months and it will accept deficiency responses on only two occasions before it decides. Quality Systems Behind Every Injectable Supplied to Georgia Georgia's acceptance of WHO-GMP is a legal position, not an informal courtesy, and it is worth stating precisely because so much competitor content implies that only a stringent authority certificate will do. Government Resolution No. 349 of 16 November 2010 sets out the list of international, regional and national GMP standards Georgia recognises, and WHO-GMP appears as the first item, followed by EC GMP, US FDA current GMP and PIC/S GMP. The resolution goes further and obliges the registering body to accept a manufacturing compliance document issued by a competent authority in accordance with any recognised standard. Georgia has separately adopted EC GMP as its national standard, but that adoption governs holders of Georgian manufacturing permits – the domestic plants – rather than foreign manufacturers filing an import registration. There is one live uncertainty that any honest supplier should hand you rather than paper over. Georgia adopted a government resolution in March 2022 dealing with the stages and conditions under which the GMP compliance document must be submitted for products in both regimes, and its consolidated text was not publicly retrievable when this article was prepared. Secondary commentary attaches dates and consequences to it that we are not willing to repeat, because we could not read the instrument. The correct step before you commit budget is to request the current text and the Agency's present practice directly from the Regulation Agency for Medical and Pharmaceutical Activities, and to ask specifically whether a WHO-GMP certificate for the finished dosage form is still sufficient on its own. That question takes one email and removes the only material unknown in an otherwise well-documented pathway. Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry Why Farbe Firma is the Trusted Injectable Manufacturer in Georgia for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling on ISO Class 5 aseptic lines and exporting to more than 30 countries. For Georgia that starting point is decisive rather than incidental: because Resolution No. 349 places WHO-GMP at the head of the recognised standards and obliges the registering body to accept a compliance document issued under it, our existing certification is the certification the national regime asks for. We do not need to manufacture a second qualification, and you do not need to wait for one. Our quality systems are built around release testing by HPLC and GC, endotoxin control by LAL, moisture determination by Karl Fischer, and stability generated under ICH Q1A(R2) and Q1B, with a Site Master File and per-product documentation maintained in a form that authenticates cleanly for foreign filings. We also build the file the way Georgia wants it rather than the way we already have it. Our dossiers are prepared in CTD and ACTD structure for the markets that require those, and for Georgia we reorganise the same underlying data into the statutory administrative and scientific-technical split, supply the API manufacturer names and addresses the generic checklist calls for by name, provide the process flow chart, and prepare the equivalence justification appropriate to the dosage form and route – which for most sterile solutions for injection is a reasoned argument rather than a clinical study. We produce the physical deliverables as a planned shipment: two standard packs, test quantities and a reference standard, each with its certificate of analysis, packed and documented so that customs and cold chain do not become the reason a three-month clock is missed. Artwork and leaflet content are supplied in a form ready for Georgian translation and attestation. Finally, we price for the market that actually exists. Georgia legislates maximum wholesale and retail prices through a published reference price catalogue and prohibits sale above them, while 58.76% of health spending comes from households directly. That combination rewards a manufacturer whose cost base allows it to sit comfortably under a statutory ceiling and still supply consistently, which is precisely the position a Gujarat-based WHO-GMP injectable plant occupies. India already supplies this market: India's own reported exports of pharmaceutical products under HS Chapter 30 to Georgia were about US$24.8 million in 2024 and US$23.7 million in 2025, and India's Ministry of External Affairs lists medicines among its top export commodities to Georgia. There is no India-Georgia pharmaceutical or health memorandum of understanding in the bilateral inventory, so nothing about this trade rests on a government-to-government arrangement – it rests on suppliers who register properly and deliver. Write to info@farbefirma.com with the molecule, presentation and volume and we will map the filing route with you. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Can an Indian manufacturer use Georgia's seven-day recognition route? No. The recognition regime is available only for products already authorised by a regulator on the list fixed by Government Resolution No. 188 of 22 October 2009, as amended in 2013, 2021 and 2022 to add Israel, Croatia and Turkiye. That list covers the EMA, the United States, Japan, Canada, Australia, New Zealand, Korea, Switzerland, Norway and the EU and EEA member states. India, CDSCO and WHO Prequalification are not on it. An Indian-registered, WHO-GMP product therefore files under the national regime. It is worth noting that the recognition route is also less generous than commonly claimed: the resulting authorisation tracks the foreign approval but is capped at five years by statute, so the widely repeated claim that it confers unlimited validity is simply wrong. Is a CTD or eCTD dossier required to register an injectable in Georgia? The statute does not prescribe the ICH Common Technical Document. It prescribes a Georgian-specific structure – an administrative part in the Georgian language in tangible form, and a scientific and technical part in Georgian, Russian or English in three identical paper copies with an electronic copy – and then lists the contents of each. Practically, a well-built CTD Module 3 contains almost everything the generic checklist asks for, so the work is reorganisation and translation rather than regeneration. Whether the Agency will accept a dossier physically organised in CTD modules is a question of current practice that we suggest confirming with the Agency, because the law neither requires nor forbids it. Does Georgia accept a WHO-GMP certificate, or is EU-GMP needed? WHO-GMP is expressly recognised. Government Resolution No. 349 of 16 November 2010 lists the GMP standards Georgia recognises, with WHO-GMP first, followed by EC GMP, US FDA current GMP and PIC/S GMP, and obliges the registering body to accept a manufacturing compliance document issued by a competent authority under any of them. Georgia's national GMP standard is EC GMP, but that requirement applies to holders of Georgian manufacturing permits rather than to importers. One caveat we state openly: a March 2022 government resolution governs the stages and conditions for submitting the GMP document, and we could not retrieve its consolidated text, so we recommend confirming current practice with the Regulation Agency for Medical and Pharmaceutical Activities before filing. What does registration cost and how long does it take? Under the Law on Registration Fees, a generic or repeatedly manufactured product in the national regime costs GEL 500 to register and GEL 200 to re-register, a new original product costs GEL 2,500, and a Type II variation in registration documentation costs GEL 50. On timing, the Agency has fourteen days for the administrative completeness check and three months to decide a primary registration, two months for re-registration, forty calendar days for a Type IB variation and twenty for a Type IA. Deficiencies may be raised on only two occasions with a cure period of up to two months, and if the applicant is not notified of a refusal within the statutory period the product is considered registered. Circulation is then permitted for five years. Do I need an import licence, and can a foreign manufacturer sell into state tenders? For ordinary sterile injectables no separate import permit is created by the Law on Medicines. Wholesale distribution, which by definition includes import, export and re-export, is subject to mandatory notification of the Agency rather than to a licence, and an import or export permit is required only for products under special control such as narcotics, psychotropics and precursors. On procurement, the consolidated Law on Public Procurement defined a participating person to include a legal person of a foreign country and required fair and non-discriminatory treatment, with foreign-language qualification documents accepted subject to a Georgian translation. Georgia adopted a new Public Procurement Law in February 2023 whose main body applies from 1 January 2025, and we have not verified how it treats foreign bidders, so confirm the current position with the State Procurement Agency before bidding. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Top Injectable Manufacturer in Djibouti – Reliable Pharmaceutical Solutions Last Updated: September 10, 2026 TL;DR: Djibouti publishes no list of foreign regulators it trusts. Its 1991 medicines law applies a country-of-origin test instead: an imported speciality may be registered only if it is already registered where it was made. That is unusually open to an Indian manufacturer — but the Ministry of Health's own strategy records that the registration system is not operated, so the gates that bind are the import visa, the pharmacist monopoly on importing, and CAMME's tenders. Key Takeaways Djibouti's Law 145/AN/91 requires an imported speciality to be registered in its country of origin; no foreign agency is named, so India is neither listed nor excluded. The Ministry of Health's supply strategy, adopted by Law 14/AN/23 of 10 March 2024, states that the registration system is not applied — the control point in practice is the import visa. Only pharmacists may import and wholesale medicines, so a foreign manufacturer cannot import in its own name and must work through a licensed local establishment. Djibouti participates in IGAD's medicines-harmonisation initiative, whose secretariat sits in Djibouti City and which shares joint WHO cGMP inspections between seven regulators. Introduction: What an Injectable Manufacturer in Djibouti Has to Prove This series usually opens by asking whether a country recognises the Indian regulator. Djibouti answers differently: it publishes no list of foreign agencies at all. Article 8 of Law 145/AN/91 of 10 February 1991 says instead that imported specialities may be registered only if they have already been registered in their country of origin, and Article 88 of Law 48/AN/99 makes the parallel demand of generics — that they be legally marketed in the producing country. The test is about where a product comes from, not about who approved it. For a Gujarat manufacturer that framing is structurally favourable: there is no list to get onto and none to be excluded from, and the burden is purely evidentiary. Djibouti is also a listed participant in the WHO Certification Scheme, which makes a WHO-format Certificate of a Pharmaceutical Product the recognised instrument for carrying that proof. But the openness has a counterpart that any serious supplier should understand before quoting: the register this law describes is, on the Ministry of Health's own account, not currently being operated. What Sets a World-Class Injectable Manufacturer in Djibouti Apart The Ministry's pharmaceutical supply strategy, adopted by Law 14/AN/23 of 10 March 2024, states plainly that the registration system run by the medicines directorate is not applied, and its action plan lists drafting the medicines-registration regulation as the first activity to complete. We could not find an implementing decree for the 1991 law's procedural articles, and we found no published fee schedule and no published timeline anywhere. Where a market's own sources leave those numbers unstated, we print neither and confirm both with the directorate. So the constraint that actually binds sits elsewhere, and it sits on the importer rather than on the factory. Article 2 of the 1991 law reserves the import, wholesale and supply of medicines to pharmacists, and Article 4 adds a nationality-or-reciprocity condition together with registration on the professional roll. A 2024 ministerial decree sets out the sequence an establishment must follow — approval, provisional authorisation, an inspection of conformity, then definitive authorisation, with annual re-inspection. The consequence is unambiguous: Farbe Firma cannot import into Djibouti in its own name, and the quality of a Djiboutian partner is the licence itself, not a commercial detail. We should also flag what we could not establish: no decree we found specifies whether the manufacturer or the local agent owns a Djiboutian marketing authorisation, and that question should be put to the directorate rather than assumed. Quality Systems Behind Every Sterile Injectable We Ship to Djibouti Because the country-of-origin test asks what the product is at home rather than who signed off abroad, the dossier has to carry its own weight. Every batch Farbe Firma releases is manufactured under WHO-GMP certification in ISO Class 5 filling environments, with terminal sterilisation or validated aseptic processing, media fills and environmental monitoring. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for bacterial endotoxins and Karl Fischer for moisture in lyophilised presentations. Stability runs on ICH Q1A protocols with Q1B photostability, on the climatic zone appropriate to a Red Sea port rather than a temperate default. Documentation is assembled in CTD format, with ACTD available where a buyer's regulator prefers it, so one dossier can serve a Djiboutian filing, a regional submission and a donor qualification. That matters more here than in most markets: Djibouti has no national quality-control laboratory and no national pharmacovigilance centre, and its own strategy records that it is not a member of the WHO Programme for International Drug Monitoring. The manufacturer's own quality system is therefore doing work a domestic laboratory does elsewhere. Planning a shipment into Djibouti or onward to the Horn of Africa? Talk to our export team about dossier formats, CoPP issuance and cold-chain routing through the Port of Djibouti. Why Farbe Firma is the Trusted Injectable Manufacturer in Djibouti for Global Buyers Djibouti is a small market attached to a very large corridor, and the two need separate answers. Domestically the numbers are modest: the World Bank puts the population at 1,168,722 in 2024, current health expenditure at 2.28% of GDP in 2023, with 28.84% paid out of pocket and 23.60% financed externally. Public purchasing runs largely through CAMME, the central medical stores, whose 2025 forecast budget, set out in a 2024 ministerial order, shows a medicines-sales line of 395,000,000 Djiboutian francs. We could not reconcile that line with the 1.48 billion franc medicines purchase budget reported for 2020 in the Ministry's own strategy; the two published figures conflict, and we print both rather than choosing. The corridor is the other half of the picture. Djibouti's port handles the overwhelming majority of landlocked Ethiopia's trade, and transit clears under a regime distinct from domestic entry: medicines entering Djibouti's own market require the Ministry of Health's visa, while goods bound onward answer to the destination regulator. For that flow the authority that matters is Ethiopia's EFDA, which WHO lists at maturity level 3 for medicines. This corrects a common assumption — India's CDSCO does appear on WHO's maturity-level listing, but the scope column reads vaccines only, so it is not a medicines credential in any market that reads that list carefully. Finally, the regional route is real, and it is administered from Djibouti City. Djibouti is one of seven regulators in IGAD's medicines-harmonisation work, which accepts dossiers in ICH CTD format, shares joint WHO cGMP site inspections between members for reliance purposes, and asks applicants to commit to marketing in at least two member states. IGAD recommends rather than approves — each authority still issues its own marketing authorisation — and IGAD itself labels its published timelines indicative. Farbe Firma's range maps closely onto the initiative's priority list, which includes oxytocin, magnesium sulphate, tranexamic acid and fixed-dose antimicrobials. Djibouti has neither signed nor ratified the African Medicines Agency treaty, so AMA is not a route here today. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Does Djibouti recognise Indian regulatory approvals such as CDSCO? Not in those terms. We found no list of recognised foreign agencies in Djiboutian law. The 1991 law requires that an imported speciality already be registered in its country of origin, which an Indian registration satisfies on its face. India is neither named nor excluded: the test is about origin, not about the approving agency. Is the Indian Pharmacopoeia accepted in Djibouti? We cannot say, in either direction. Djiboutian law provides for a ministerial order listing the pharmacopoeias that may be referenced and prohibits reference to any other. We were unable to locate that order, so whether the Indian Pharmacopoeia appears on it is unknown to us. Farbe Firma releases to USP, BP, IP or EP as a buyer requires. Can Farbe Firma import into Djibouti directly? No. Djiboutian law reserves the import, wholesale and supply of medicines to pharmacists, with a nationality-or-reciprocity condition and registration on the professional roll, and a 2024 decree sets out the approval and inspection sequence an establishment must complete. A foreign manufacturer supplies through a licensed local establishment or to CAMME, not in its own name. What does registration in Djibouti cost, and how long does it take? We are not going to print a number for either. No fee schedule and no statutory timeline were found in any published Djiboutian instrument we could read, and the Ministry's own strategy records that the registration regulation is still to be drafted. Both should be confirmed with the medicines directorate before a launch plan depends on them. Does Farbe Firma supply the Ethiopia transit corridor through Djibouti? Yes, and the two flows are worth separating. Goods entering Djibouti's domestic market need the Ministry of Health's import visa; goods in transit to Ethiopia answer to Ethiopia's EFDA, which WHO lists at maturity level 3 for medicines. Because both countries participate in IGAD, a single CTD dossier and a shared cGMP inspection can serve both ends of the corridor. Farbe Firma Pvt Ltd — WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. Exporting to 30+ countries. Email: info@farbefirma.com | Request a Quote / View Products / FAQ / Blog

Last Updated: September 12, 2026 TL;DR: Solomon Islands has no medicines register. The Pharmacy and Poisons Act has been in force since 1941 and licenses sellers and premises, not products, so there is no dossier to file. Section 43 makes the British Pharmacopoeia the standard of quality for every medicine sold. What actually binds a consignment is the importer's own licence, the Ministry's tender, and the donor rules attached to malaria and tuberculosis money. Key Takeaways There is no product registration system. The Act creates registers of pharmacists and of premises, and none for medicines. Anyone quoting a Solomon Islands registration timeline is describing something that does not exist. Section 43 makes the British Pharmacopoeia the standard of quality and composition for all medicines, and it was re-enacted in 1978 rather than merely inherited. The Indian Pharmacopoeia is named nowhere in the Act. Import lawfulness turns on the scope of the importer's own licence, not on the product and not on the foreign plant. No CPP, GMP certificate or overseas inspection appears anywhere in the statute. For Global Fund-financed artesunate and tuberculosis injectables, WHO prequalification or an Expert Review Panel recommendation is the route. For everything else the policy defers to the standard of the country of use. Introduction: What an Injectable Manufacturer in Solomon Islands Has to Prove Every market in this series opens with the same question — does the country name the foreign regulators whose decisions it will lean on, and is India's CDSCO among them? Solomon Islands answers by not asking the question at all. There is no reliance list, and there is no product register for a reliance list to feed. The Pharmacy and Poisons Act, in force since 28 July 1941 and consolidated in the 1996 revised edition, creates a register of pharmacists and a register of premises. It creates nothing for medicines. That reframes the whole exercise. This is not a dossier market, and a supplier who offers you a registration timeline for it is describing a process that does not exist. Section 49 makes an import unlawful if the importer is not entitled under their licence to sell the thing being imported. The gate sits on the buyer, not on the product. What Sets a World-Class Injectable Manufacturer in Solomon Islands Apart Section 43 provides that the British Pharmacopoeia, in the edition for the time being in force, is the standard of quality or composition for all drugs and medicines. That is exclusive drafting — the standard, for all medicines — and it carries a detail worth noticing, because the section was re-enacted in 1978, the year of independence. Indian sterile plants routinely release to BP monographs, so this aligns well; an IP-only specification is the weak flank. The second thing to understand is where quality is actually policed, which is procurement rather than law. Public medicines move through the National Medical Store in Honiara to eighteen second-level stores and on to more than 350 service delivery points, free at the point of use. In 2023 the Ministry put bidding onto a digital platform and made expiry information and minimum delivery periods mandatory bid conditions. Those tender terms, not the 1941 statute, are where a manufacturer's certifications actually get read. Quality Systems Behind Every Sterile Injectable We Ship to Solomon Islands Farbe Firma manufactures under WHO-GMP certification in ISO Class 5 filling environments, with validated aseptic process simulation, environmental monitoring and container-closure integrity testing. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for bacterial endotoxins and Karl Fischer for moisture in lyophilised vials. Stability follows ICH Q1A with Q1B photostability. Dossiers are built in CTD structure with ACTD available — not because Solomon Islands asks for one, but because a tender or a donor will. Two local realities shape the specification more than any rule does. Solomon Islands publishes no national stability condition; the WHO reference table places it at 30°C and 65% relative humidity, and that entry is derived from climate data rather than confirmed by the regulator, so we found no binding requirement and therefore claim none. We hold Zone IVb data because it envelopes that. And the last leg runs by boat, light aircraft and motorbike to clinics often staffed by one nurse, across nine provinces and ninety inhabited islands, which argues for long remaining shelf life far more than for cold chain. Working out whether Solomon Islands is reachable for your product? Talk to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Solomon Islands for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For Solomon Islands we can supply WHO-format GMP and pharmaceutical product certificates, BP-referenced release data and full stability packages for a tender file. What we cannot do is import, and no certificate we hold cures that: every licence in the Act attaches to a local person and local premises. We hold no Solomon Islands licence and recommend no partner we have not verified. The binding quality gate for part of the portfolio is a donor rule rather than a national one. The Global Fund accepts WHO prequalification, a pre-2015 stringent regulatory authority, a WHO Listed Authority or its Expert Review Panel — and India's CDSCO is none of those for medicines, since WHO lists it for vaccines only. But that gate applies solely to antiretroviral, anti-tuberculosis and antimalarial finished products; for everything else the policy defers to the standard of the country of use. Malaria is why this matters here: WHO recorded 147,145 presumed and confirmed cases in 2023, with 99% of the population living in a high-transmission area, and injectable artesunate has been national policy for severe malaria since 2018. The financing picture is unusual and easy to misread. Population was 838,645 in 2025; current health expenditure was 5.36% of GDP in 2023 at US$111 per head, putting the national total near US$89 million. Out-of-pocket spending was just 3.16% — among the lowest anywhere — but that figure is partly an artefact of the 33.87% financed externally in the same year, up from 27.37% in 2022. A third of the denominator is donor money, so the low household share is not by itself evidence of financial protection. We will not print a market-size figure: the two customs series we found disagree and both look implausible against US$89 million. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Does Solomon Islands recognise India's CDSCO or Indian regulatory approval? There is nothing to recognise it with. No instrument names any foreign medicines regulator — not CDSCO, and equally not the TGA, MHRA, US FDA or EMA — because the Act contains no agency-recognition mechanism and no product register. Where CDSCO status does bite is inside Global Fund money, and there it does not qualify. Is the Indian Pharmacopoeia accepted in Solomon Islands? Not on any published basis. Section 43 names the British Pharmacopoeia exclusively, as the standard for all drugs and medicines, and the Act's own schedule uses BP and BPC designations throughout. This is not fatal for an Indian supplier, because BP release is standard practice in Indian sterile plants — but an IP-only specification has no statutory footing, and a supplier claiming otherwise is reading something that is not there. Does a foreign manufacturer need a local partner in Solomon Islands? Yes, unavoidably. Every authorisation in the Act attaches to a local person or body corporate operating local premises: a Medicine Licence is granted to a licensed storekeeper and names the articles that may be sold, a Poisons Licence covers one place of business, and a body corporate dealing in drugs must trade under a registered pharmacist as superintendent. A foreign manufacturer holds nothing and can hold nothing. What does registration cost in Solomon Islands, and how long does it take? Neither question has an answer, and that is the finding rather than a gap. There is no registration, so there is no registration fee and no statutory decision clock anywhere in the Act — the only figures in the statute are legacy amounts that show its age. The Government's own trade portal publishes no medicines procedure at all. Confirm current practice directly with the Ministry of Health and Medical Services. What actually controls an injectable consignment arriving in Solomon Islands today? Three things, none of them a product approval. The importer's licence scope, under section 49, which makes the import unlawful if the licence does not cover the article. A discretionary power for the Under Secretary for Health to certify goods to Customs as not to be imported. And a separate Board licence for anything on the poisons list, which for an injectable portfolio notably includes insulin. A pharmacy permit is also reported in practice, though we found no instrument establishing one. Website: www.farbefirma.org | Email: info@farbefirma.com | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog